\relax 
\providecommand\hyper@newdestlabel[2]{}
\providecommand\zref@newlabel[2]{}
\providecommand*{\memsetcounter}[2]{}
\bbl@cs{beforestart}
\catcode `"\active 
\providecommand\HyperFirstAtBeginDocument{\AtBeginDocument}
\HyperFirstAtBeginDocument{\ifx\hyper@anchor\@undefined
\global\let\oldcontentsline\contentsline
\gdef\contentsline#1#2#3#4{\oldcontentsline{#1}{#2}{#3}}
\global\let\oldnewlabel\newlabel
\gdef\newlabel#1#2{\newlabelxx{#1}#2}
\gdef\newlabelxx#1#2#3#4#5#6{\oldnewlabel{#1}{{#2}{#3}}}
\AtEndDocument{\ifx\hyper@anchor\@undefined
\let\contentsline\oldcontentsline
\let\newlabel\oldnewlabel
\fi}
\fi}
\global\let\hyper@last\relax 
\gdef\HyperFirstAtBeginDocument#1{#1}
\providecommand*\HyPL@Entry[1]{}
\abx@aux@refcontext{none/global//global/global}
\abx@aux@refsection{1}{1}
\HyPL@Entry{0<</S/r>>}
\providecommand \oddpage@label [2]{}
\@writefile{toc}{\boolfalse {citerequest}\boolfalse {citetracker}\boolfalse {pagetracker}\boolfalse {backtracker}\relax }
\@writefile{lof}{\boolfalse {citerequest}\boolfalse {citetracker}\boolfalse {pagetracker}\boolfalse {backtracker}\relax }
\@writefile{lot}{\boolfalse {citerequest}\boolfalse {citetracker}\boolfalse {pagetracker}\boolfalse {backtracker}\relax }
\babel@aux{english}{}
\newlabel{refsection:1}{{\M@TitleReference {}{}}{i}{}{Doc-Start}{}}
\HyPL@Entry{2<</S/r>>}
\@writefile{toc}{\contentsline {chapter}{Summary}{i}{chapter*.1}\protected@file@percent }
\newlabel{cha:summary}{{\M@TitleReference {}{Zusammenfassung}}{iii}{Zusammenfassung\markboth {ZUSAMMENFASSUNG}{}}{chapter*.2}{}}
\@writefile{toc}{\contentsline {chapter}{Zusammenfassung}{iii}{chapter*.2}\protected@file@percent }
\abx@aux@refsection{2}{1}
\HyPL@Entry{10<</S/D>>}
\newlabel{refsection:2}{{\M@TitleReference {}{}}{1}{}{Item.2}{}}
\@writefile{toc}{\contentsline {section}{\numberline {0.1}maybe fun to add.}{1}{section.0.1}\protected@file@percent }
\abx@aux@cite{Kirby1944}
\abx@aux@segm{2}{0}{Kirby1944}
\abx@aux@cite{Naghavi2024}
\abx@aux@segm{2}{0}{Naghavi2024}
\abx@aux@cite{Bates1998}
\abx@aux@segm{2}{0}{Bates1998}
\abx@aux@cite{Regoes2004}
\abx@aux@segm{2}{0}{Regoes2004}
\@writefile{lof}{\addvspace {10pt}}
\@writefile{lot}{\addvspace {10pt}}
\@writefile{toc}{\contentsline {chapter}{\chapternumberline {1}introduction}{3}{chapter.1}\protected@file@percent }
\abx@aux@cite{Bell2014}
\abx@aux@segm{2}{0}{Bell2014}
\abx@aux@cite{Rahman2023}
\abx@aux@segm{2}{0}{Rahman2023}
\abx@aux@cite{Leekha2011}
\abx@aux@segm{2}{0}{Leekha2011}
\abx@aux@cite{Kable1980}
\abx@aux@segm{2}{0}{Kable1980}
\abx@aux@cite{Delp1980}
\abx@aux@segm{2}{0}{Delp1980}
\abx@aux@cite{Skylakakis1981}
\abx@aux@segm{2}{0}{Skylakakis1981}
\abx@aux@cite{Bonhoeffer1997}
\abx@aux@segm{2}{0}{Bonhoeffer1997}
\abx@aux@cite{Tepekule2017}
\abx@aux@segm{2}{0}{Tepekule2017}
\abx@aux@cite{Uecker2021}
\abx@aux@segm{2}{0}{Uecker2021}
\abx@aux@cite{Bell2014}
\abx@aux@segm{2}{0}{Bell2014}
\abx@aux@cite{Rahman2023}
\abx@aux@segm{2}{0}{Rahman2023}
\abx@aux@cite{Jernberg2007}
\abx@aux@segm{2}{0}{Jernberg2007}
\abx@aux@cite{Tamma2012}
\abx@aux@segm{2}{0}{Tamma2012}
\@writefile{toc}{\contentsline {subsection}{Treatment Strategies}{4}{section*.6}\protected@file@percent }
\abx@aux@cite{Goldberg2012}
\abx@aux@segm{2}{0}{Goldberg2012}
\abx@aux@cite{siedentop_metaanalysis_2024}
\abx@aux@segm{2}{0}{siedentop_metaanalysis_2024}
\abx@aux@cite{siedentop_metaanalysis_2024}
\abx@aux@segm{2}{0}{siedentop_metaanalysis_2024}
\abx@aux@cite{Angst2021}
\abx@aux@segm{2}{0}{Angst2021}
\abx@aux@cite{Loewe1926}
\abx@aux@segm{2}{0}{Loewe1926}
\abx@aux@cite{Bliss1939}
\abx@aux@segm{2}{0}{Bliss1939}
\abx@aux@cite{Yeh2006}
\abx@aux@segm{2}{0}{Yeh2006}
\abx@aux@cite{Chevereau2015a}
\abx@aux@segm{2}{0}{Chevereau2015a}
\abx@aux@cite{Kavcic2020}
\abx@aux@segm{2}{0}{Kavcic2020}
\@writefile{toc}{\contentsline {subsection}{Population Dynamics under Combination Therapy}{5}{section*.7}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {1.1}Thesis outline}{6}{section.1.1}\protected@file@percent }
\abx@aux@refsection{3}{9}
\newlabel{refsection:3}{{\M@TitleReference {}{}}{9}{}{section*.8}{}}
\@writefile{lof}{\addvspace {10pt}}
\@writefile{lot}{\addvspace {10pt}}
\@writefile{toc}{\contentsline {chapter}{\chapternumberline {2}The Impact of Treatment Strategies on the Epidemiological Dynamics of Plasmid-Conferred Antibiotic Resistance}{11}{chapter.2}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {2.1}abstract}{11}{section.2.1}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {2.2}Introduction}{11}{section.2.2}\protected@file@percent }
\abx@aux@cite{Kable1980}
\abx@aux@segm{3}{0}{Kable1980}
\abx@aux@cite{Delp1980}
\abx@aux@segm{3}{0}{Delp1980}
\abx@aux@cite{Skylakakis1981}
\abx@aux@segm{3}{0}{Skylakakis1981}
\abx@aux@cite{Goldberg2012}
\abx@aux@segm{3}{0}{Goldberg2012}
\abx@aux@cite{siedentop_metaanalysis_2024}
\abx@aux@segm{3}{0}{siedentop_metaanalysis_2024}
\abx@aux@cite{VanDuijn2018}
\abx@aux@segm{3}{0}{VanDuijn2018}
\abx@aux@cite{Uecker2021}
\abx@aux@segm{3}{0}{Uecker2021}
\abx@aux@cite{Bonhoeffer1997}
\abx@aux@segm{3}{0}{Bonhoeffer1997}
\abx@aux@cite{Tepekule2017}
\abx@aux@segm{3}{0}{Tepekule2017}
\abx@aux@cite{siedentop_metaanalysis_2024}
\abx@aux@segm{3}{0}{siedentop_metaanalysis_2024}
\abx@aux@cite{Angst2021}
\abx@aux@segm{3}{0}{Angst2021}
\abx@aux@cite{Huisman2022}
\abx@aux@segm{3}{0}{Huisman2022}
\abx@aux@cite{Sutter2016}
\abx@aux@segm{3}{0}{Sutter2016}
\@writefile{toc}{\contentsline {section}{\numberline {2.3}Results}{14}{section.2.3}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Multidrug strategies keep the overall number of infections lowest and best suppress single resistance.}{14}{section*.11}\protected@file@percent }
\@writefile{lot}{\contentsline {table}{\numberline {2.1}{\ignorespaces \textbf  {Parameter sets} and $R_0$ used in the three experiments: $c_\mitphi $ is the proportion of admitted patients with resistance profile $\mitphi $, $\mittau $ denotes the probability that a patient is replaced with a new patient sampled from the community and $\mitbeta $ denotes the infection probability.\relax }}{14}{table.caption.9}\protected@file@percent }
\providecommand*\caption@xref[2]{\@setref\relax\@undefined{#1}}
\newlabel{tab:exp_par}{{\M@TitleReference {2.1}{\textbf  {Parameter sets} and $R_0$ used in the three experiments: $c_\mitphi $ is the proportion of admitted patients with resistance profile $\mitphi $, $\mittau $ denotes the probability that a patient is replaced with a new patient sampled from the community and $\mitbeta $ denotes the infection probability.\relax }}{14}{\textbf {Parameter sets} and $R_0$ used in the three experiments: $c_\phi $ is the proportion of admitted patients with resistance profile $\phi $, $\tau $ denotes the probability that a patient is replaced with a new patient sampled from the community and $\beta $ denotes the infection probability.\relax }{table.caption.9}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.1}{\ignorespaces  Panels A--C show the mean frequency of uninfected (grey), single-resistant infected (blue), and double-resistant infected wells (green) during the last four transfers of the three scenarios. Circles represent replicates (n = 4), and bars represent means. Within resistance categories, bars not sharing a letter are significantly different (pairwise Tukey post hoc test, $p<0.05$; ANOVA tables and all p-values can be found in \leavevmode {\color {blue}Table~S2.34} -- \leavevmode {\color {blue}S2.50}). \relax }}{15}{figure.caption.10}\protected@file@percent }
\newlabel{fig:end_anova}{{\M@TitleReference {2.1}{ Panels A--C show the mean frequency of uninfected (grey), single-resistant infected (blue), and double-resistant infected wells (green) during the last four transfers of the three scenarios. Circles represent replicates (n = 4), and bars represent means. Within resistance categories, bars not sharing a letter are significantly different (pairwise Tukey post hoc test, $p<0.05$; ANOVA tables and all p-values can be found in \leavevmode {\color {blue}Table~S2.34} -- \leavevmode {\color {blue}S2.50}). \relax }}{15}{ Panels A--C show the mean frequency of uninfected (grey), single-resistant infected (blue), and double-resistant infected wells (green) during the last four transfers of the three scenarios. Circles represent replicates (n = 4), and bars represent means. Within resistance categories, bars not sharing a letter are significantly different (pairwise Tukey post hoc test, $p<0.05$; ANOVA tables and all p-values can be found in \sitab {34} -- \siref {50}). \relax }{figure.caption.10}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.2}{\ignorespaces  Frequencies of resistance profiles over time during the \textit  {maximum-emergence}~scenario. Panels (A--F) show the six tested strategies. Dots and bars show the mean and min/max interval of the four replicates. The dash-dotted line shows the mean value of 100 stochastic simulations based on the instruction set used in the \textit  {in vitro} experiment (\textit  {validation simulation}). The solid line shows the mean value of 100 simulations with randomly created instruction sets based on the parameter set used in the experiment (\textit  {variation simulations}). The shaded error band indicates the 95-percentile interval between the \textit  {variation simulations}.\relax }}{16}{figure.caption.12}\protected@file@percent }
\newlabel{fig:exp3}{{\M@TitleReference {2.2}{ Frequencies of resistance profiles over time during the \textit  {maximum-emergence}~scenario. Panels (A--F) show the six tested strategies. Dots and bars show the mean and min/max interval of the four replicates. The dash-dotted line shows the mean value of 100 stochastic simulations based on the instruction set used in the \textit  {in vitro} experiment (\textit  {validation simulation}). The solid line shows the mean value of 100 simulations with randomly created instruction sets based on the parameter set used in the experiment (\textit  {variation simulations}). The shaded error band indicates the 95-percentile interval between the \textit  {variation simulations}.\relax }}{16}{ Frequencies of resistance profiles over time during the \textit {maximum-emergence}~scenario. Panels (A--F) show the six tested strategies. Dots and bars show the mean and min/max interval of the four replicates. The dash-dotted line shows the mean value of 100 stochastic simulations based on the instruction set used in the \textit {in vitro} experiment (\textit {validation simulation}). The solid line shows the mean value of 100 simulations with randomly created instruction sets based on the parameter set used in the experiment (\textit {variation simulations}). The shaded error band indicates the 95-percentile interval between the \textit {variation simulations}.\relax }{figure.caption.12}{}}
\@writefile{toc}{\contentsline {paragraph}{All treatment strategies fail to contain pre-existing double resistance.}{17}{section*.13}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Treatment strategies affect the emergence of double resistance.}{17}{section*.14}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Combination therapy suppresses the emergence of double resistance by preventing superinfections.}{18}{section*.15}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Treatment strategies influence the emergence of double resistance within superinfected wells.}{18}{section*.16}\protected@file@percent }
\@writefile{lof}{\contentsline {figure}{\numberline {2.3}{\ignorespaces  Analysis of the emergence of double resistance \textit  {in vitro} and superinfection between single resistant $A_r$ and $B_r$ wells during the \textit  {maximum-emergence}~scenario, from transfer four onwards. Each dot corresponds to data from a single plate, with each plate representing a distinct treatment arm, encompassing 376 patients for one transfer. Mean values are represented by red bars. Bars not sharing a letter are significantly different ($p < 0.05$, ANOVA tables and pairwise Tukey post hoc results can be found in \leavevmode {\color {blue}Table~S2.51} -- \leavevmode {\color {blue}S2.56}). \textbf  {A)} Number of newly emerged cases of double resistance per plate ($n_{{\symcal E}}$), normalised to the total number of patients ($n_P = 376$). \textbf  {B)} Number of superinfections per plate ($n_{\symcal S}$), normalised to $n_P$. \textbf  {C)} Proportion of superinfected wells treated with A, B, AB, or none that develop double resistance. \relax }}{19}{figure.caption.17}\protected@file@percent }
\newlabel{fig:emergence}{{\M@TitleReference {2.3}{ Analysis of the emergence of double resistance \textit  {in vitro} and superinfection between single resistant $A_r$ and $B_r$ wells during the \textit  {maximum-emergence}~scenario, from transfer four onwards. Each dot corresponds to data from a single plate, with each plate representing a distinct treatment arm, encompassing 376 patients for one transfer. Mean values are represented by red bars. Bars not sharing a letter are significantly different ($p < 0.05$, ANOVA tables and pairwise Tukey post hoc results can be found in \leavevmode {\color {blue}Table~S2.51} -- \leavevmode {\color {blue}S2.56}). \textbf  {A)} Number of newly emerged cases of double resistance per plate ($n_{{\symcal E}}$), normalised to the total number of patients ($n_P = 376$). \textbf  {B)} Number of superinfections per plate ($n_{\symcal S}$), normalised to $n_P$. \textbf  {C)} Proportion of superinfected wells treated with A, B, AB, or none that develop double resistance. \relax }}{19}{ Analysis of the emergence of double resistance \textit {in vitro} and superinfection between single resistant $A_r$ and $B_r$ wells during the \textit {maximum-emergence}~scenario, from transfer four onwards. Each dot corresponds to data from a single plate, with each plate representing a distinct treatment arm, encompassing 376 patients for one transfer. Mean values are represented by red bars. Bars not sharing a letter are significantly different ($p < 0.05$, ANOVA tables and pairwise Tukey post hoc results can be found in \sitab {51} -- \siref {56}). \textbf {A)} Number of newly emerged cases of double resistance per plate ($n_{{\mathcal E}}$), normalised to the total number of patients ($n_P = 376$). \textbf {B)} Number of superinfections per plate ($n_{\mathcal S}$), normalised to $n_P$. \textbf {C)} Proportion of superinfected wells treated with A, B, AB, or none that develop double resistance. \relax }{figure.caption.17}{}}
\@writefile{toc}{\contentsline {paragraph}{Computational model corroborates the robustness of experimental outcomes.}{19}{section*.18}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{\textit  {In silico} sensitivity analysis indicates that the superiority of combination therapy is robust.}{20}{section*.19}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {2.4}Discussion}{21}{section.2.4}\protected@file@percent }
\abx@aux@cite{eucast_disk2024}
\abx@aux@segm{3}{0}{eucast_disk2024}
\abx@aux@cite{BAG2015}
\abx@aux@segm{3}{0}{BAG2015}
\@writefile{lof}{\contentsline {figure}{\numberline {2.4}{\ignorespaces  Effectiveness of the five treatment strategies in maximising the frequency of uninfected individuals across randomly generated parameter sets. Strategies not significantly better than any other are marked as losers (pastel red), and those significantly worse than all others as single losers (dark red). Strategies not significantly worse than any other are classified as winners (pastel blue), and those significantly better than all others as single winners (dark blue). Strategies without significant differences were excluded. \textbf  {(A)} 10{,}000 parameter sets with pre-existing double resistance. 606/10{,}000 sets yielded no significant difference between the strategies. \textbf  {(B)} 10{,}000 parameter sets without pre-existing double resistance. 100/10{,}000 sets yielded no significant difference between the strategies. \relax }}{22}{figure.caption.20}\protected@file@percent }
\newlabel{fig:senstivity_analysis}{{\M@TitleReference {2.4}{ Effectiveness of the five treatment strategies in maximising the frequency of uninfected individuals across randomly generated parameter sets. Strategies not significantly better than any other are marked as losers (pastel red), and those significantly worse than all others as single losers (dark red). Strategies not significantly worse than any other are classified as winners (pastel blue), and those significantly better than all others as single winners (dark blue). Strategies without significant differences were excluded. \textbf  {(A)} 10{,}000 parameter sets with pre-existing double resistance. 606/10{,}000 sets yielded no significant difference between the strategies. \textbf  {(B)} 10{,}000 parameter sets without pre-existing double resistance. 100/10{,}000 sets yielded no significant difference between the strategies. \relax }}{22}{ Effectiveness of the five treatment strategies in maximising the frequency of uninfected individuals across randomly generated parameter sets. Strategies not significantly better than any other are marked as losers (pastel red), and those significantly worse than all others as single losers (dark red). Strategies not significantly worse than any other are classified as winners (pastel blue), and those significantly better than all others as single winners (dark blue). Strategies without significant differences were excluded. \textbf {(A)} 10{,}000 parameter sets with pre-existing double resistance. 606/10{,}000 sets yielded no significant difference between the strategies. \textbf {(B)} 10{,}000 parameter sets without pre-existing double resistance. 100/10{,}000 sets yielded no significant difference between the strategies. \relax }{figure.caption.20}{}}
\abx@aux@cite{Headd2018}
\abx@aux@segm{3}{0}{Headd2018}
\abx@aux@cite{Angst2021}
\abx@aux@segm{3}{0}{Angst2021}
\abx@aux@cite{Sutter2016}
\abx@aux@segm{3}{0}{Sutter2016}
\abx@aux@cite{Huisman2022}
\abx@aux@segm{3}{0}{Huisman2022}
\abx@aux@cite{Feher2012}
\abx@aux@segm{3}{0}{Feher2012}
\@writefile{toc}{\contentsline {section}{\numberline {2.5}Methods}{25}{section.2.5}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Drugs and Media.}{25}{section*.21}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Strains and Plasmids.}{25}{section*.22}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Treatment arms.}{25}{section*.23}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Assay plates.}{25}{section*.24}\protected@file@percent }
\newlabel{par:setup}{{\M@TitleReference {2.5}{Experimental procedure. }}{26}{Experimental procedure}{section*.25}{}}
\@writefile{toc}{\contentsline {paragraph}{Experimental procedure. }{26}{section*.25}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Turnover.}{26}{section*.26}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Infections.}{26}{section*.27}\protected@file@percent }
\newlabel{par:phenotyping}{{\M@TitleReference {2.5}{Resistance Profiles.}}{27}{Resistance Profiles}{section*.28}{}}
\@writefile{toc}{\contentsline {paragraph}{Resistance Profiles.}{27}{section*.28}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Scenarios.}{27}{section*.29}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Instruction Sets.}{28}{section*.30}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Computational Model.}{28}{section*.31}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{\textit  {In Silico} Sensitivity Analysis.}{28}{section*.32}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Data Availability}{29}{section*.33}\protected@file@percent }
\abx@aux@refsection{4}{30}
\abx@aux@cite{Sutter2016}
\abx@aux@segm{4}{0}{Sutter2016}
\abx@aux@cite{Huisman2022}
\abx@aux@segm{4}{0}{Huisman2022}
\newlabel{refsection:4}{{\M@TitleReference {}{}}{30}{}{section*.35}{}}
\abx@aux@cite{Feher2012}
\abx@aux@segm{4}{0}{Feher2012}
\abx@aux@cite{Carattoli2005}
\abx@aux@segm{4}{0}{Carattoli2005}
\abx@aux@cite{Sutter2016}
\abx@aux@segm{4}{0}{Sutter2016}
\abx@aux@cite{Huisman2022Conjugation}
\abx@aux@segm{4}{0}{Huisman2022Conjugation}
\abx@aux@cite{Feher2012}
\abx@aux@segm{4}{0}{Feher2012}
\abx@aux@cite{Carattoli2005}
\abx@aux@segm{4}{0}{Carattoli2005}
\@writefile{toc}{\contentsline {section}{\numberline {2.6}Supplementary Information Chapter 2}{31}{section.2.6}\protected@file@percent }
\newlabel{ssec:si_methods}{{\M@TitleReference {2.6}{SI Methods}}{31}{SI Methods}{section*.36}{}}
\@writefile{toc}{\contentsline {subsection}{SI Methods}{31}{section*.36}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Strains}{31}{section*.37}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Drugs.}{31}{section*.38}\protected@file@percent }
\abx@aux@cite{Virtanen2020}
\abx@aux@segm{4}{0}{Virtanen2020}
\abx@aux@cite{Virtanen2020}
\abx@aux@segm{4}{0}{Virtanen2020}
\newlabel{par: conj_protocol}{{\M@TitleReference {2.6}{Conjugation Protocol.}}{32}{Conjugation Protocol}{section*.39}{}}
\@writefile{toc}{\contentsline {paragraph}{Conjugation Protocol.}{32}{section*.39}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Plasmid costs}{32}{section*.40}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Segregational Loss}{32}{section*.41}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Growth rates and bacterial density.}{33}{section*.42}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Basic Reproductive Number.}{33}{section*.43}\protected@file@percent }
\newlabel{eq:R0}{{S1}{33}{Basic Reproductive Number}{equation.2.6.1}{}}
\newlabel{par:x_phenotyping}{{\M@TitleReference {2.6}{Phenotyping -- Limitations. }}{33}{Phenotyping -- Limitations}{section*.44}{}}
\@writefile{toc}{\contentsline {paragraph}{Phenotyping -- Limitations. }{33}{section*.44}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Advanced Resistance Profiles}{35}{section*.45}\protected@file@percent }
\newlabel{ssec:statistics}{{\M@TitleReference {2.6}{Statistical Analysis. }}{35}{Statistical Analysis}{section*.46}{}}
\@writefile{toc}{\contentsline {paragraph}{Statistical Analysis. }{35}{section*.46}\protected@file@percent }
\abx@aux@cite{Virtanen2020}
\abx@aux@segm{4}{0}{Virtanen2020}
\abx@aux@cite{seabold2010statsmodels}
\abx@aux@segm{4}{0}{seabold2010statsmodels}
\@writefile{toc}{\contentsline {paragraph}{\textit  {Maximum-emergence}~scenario: Predicting the Emergence Probability.}{36}{section*.47}\protected@file@percent }
\newlabel{eq:Pe}{{S2}{36}{\textit {Maximum-emergence}~scenario: Predicting the Emergence Probability}{equation.2.6.2}{}}
\newlabel{ssec:si_results}{{\M@TitleReference {2.6}{SI Results}}{37}{SI Results}{section*.48}{}}
\@writefile{toc}{\contentsline {subsection}{SI Results}{37}{section*.48}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Impact of Treatment on the Emergence of Double Resistance.}{37}{section*.49}\protected@file@percent }
\newlabel{ssec:inocula}{{\M@TitleReference {2.6}{Treatment strategies influence the number of bacteria inoculating superinfections. }}{37}{Treatment strategies influence the number of bacteria inoculating superinfections}{section*.50}{}}
\@writefile{toc}{\contentsline {paragraph}{Treatment strategies influence the number of bacteria inoculating superinfections. }{37}{section*.50}\protected@file@percent }
\abx@aux@cite{Cates1951}
\abx@aux@segm{4}{0}{Cates1951}
\abx@aux@cite{Jawetz1957}
\abx@aux@segm{4}{0}{Jawetz1957}
\abx@aux@cite{Ocampo2014}
\abx@aux@segm{4}{0}{Ocampo2014}
\abx@aux@cite{Angermayr2022}
\abx@aux@segm{4}{0}{Angermayr2022}
\newlabel{ssec:antagonism}{{\M@TitleReference {2.6}{Antagonism.}}{38}{Antagonism}{section*.51}{}}
\@writefile{toc}{\contentsline {paragraph}{Antagonism.}{38}{section*.51}\protected@file@percent }
\newlabel{ssec: model}{{\M@TitleReference {2.6}{SI Computational Model}}{38}{SI Computational Model}{section*.52}{}}
\@writefile{toc}{\contentsline {subsection}{SI Computational Model}{38}{section*.52}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Stochasticity}{38}{section*.53}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Transition Probabilities.}{39}{section*.54}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Transition Probabilities for Transfer 1.}{39}{section*.55}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Choice of Model.}{39}{section*.56}\protected@file@percent }
\newlabel{par:contamination}{{\M@TitleReference {2.6}{Contamination of the Transition Matrix. }}{40}{Contamination of the Transition Matrix}{section*.57}{}}
\@writefile{toc}{\contentsline {paragraph}{Contamination of the Transition Matrix. }{40}{section*.57}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Filtered Transition Probabilities.}{41}{section*.58}\protected@file@percent }
\@writefile{lof}{\contentsline {figure}{\numberline {2.5}{\ignorespaces  Schematic illustrating the procedure used in the experiment for transfers T and T+1 in the liquid handling platform after adding medium and drugs to the \textit  {assay plates}. Every transfer (day), we provide new \textit  {assay} and \textit  {agar plates}. Plates from the previous transfers are removed. To inoculate the new \textit  {assay plates} with newly admitted patients from the strain plate, along with staying patients and infection between patients from the previous \textit  {assay plate}, we use a pintool with retractable pins (dashed lines). Discharged patients are not transferred (pins retracted) to the new assay plates. Plates are then automatically transferred (solid lines) to the incubator for overnight incubation. Subsequently, we replicate each \textit  {assay plate} onto four agar plates using the pintool. These plates are treated with antibiotics A, B, and AB, and one remains untreated. Once the agar plates have been incubated overnight, we capture images (dotted lines) to determine the resistance profile $\mitphi _i$ for each well $i$.\relax }}{42}{figure.caption.59}\protected@file@percent }
\newlabel{fig:procedure}{{\M@TitleReference {2.5}{ Schematic illustrating the procedure used in the experiment for transfers T and T+1 in the liquid handling platform after adding medium and drugs to the \textit  {assay plates}. Every transfer (day), we provide new \textit  {assay} and \textit  {agar plates}. Plates from the previous transfers are removed. To inoculate the new \textit  {assay plates} with newly admitted patients from the strain plate, along with staying patients and infection between patients from the previous \textit  {assay plate}, we use a pintool with retractable pins (dashed lines). Discharged patients are not transferred (pins retracted) to the new assay plates. Plates are then automatically transferred (solid lines) to the incubator for overnight incubation. Subsequently, we replicate each \textit  {assay plate} onto four agar plates using the pintool. These plates are treated with antibiotics A, B, and AB, and one remains untreated. Once the agar plates have been incubated overnight, we capture images (dotted lines) to determine the resistance profile $\mitphi _i$ for each well $i$.\relax }}{42}{ Schematic illustrating the procedure used in the experiment for transfers T and T+1 in the liquid handling platform after adding medium and drugs to the \textit {assay plates}. Every transfer (day), we provide new \textit {assay} and \textit {agar plates}. Plates from the previous transfers are removed. To inoculate the new \textit {assay plates} with newly admitted patients from the strain plate, along with staying patients and infection between patients from the previous \textit {assay plate}, we use a pintool with retractable pins (dashed lines). Discharged patients are not transferred (pins retracted) to the new assay plates. Plates are then automatically transferred (solid lines) to the incubator for overnight incubation. Subsequently, we replicate each \textit {assay plate} onto four agar plates using the pintool. These plates are treated with antibiotics A, B, and AB, and one remains untreated. Once the agar plates have been incubated overnight, we capture images (dotted lines) to determine the resistance profile $\phi _i$ for each well $i$.\relax }{figure.caption.59}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.6}{\ignorespaces \textbf  {\textit  {Prevention}~scenario:} Frequencies of resistance profiles (colours) over time during the \textit  {prevention}~scenario. The dots show the experimental measurements, and the error bar indicates the min/max interval between the replicates. The dash-dotted line shows the mean value of 100 stochastic simulations based on the instruction set used in the in vitro experiment. The solid line represents the mean value of 100 simulations with randomly created instruction sets based on the parameter set used in the experiment. The shaded error band indicates the 95-percentile interval between the simulations.\relax }}{43}{figure.caption.60}\protected@file@percent }
\newlabel{fig:exp1}{{\M@TitleReference {2.6}{\textbf  {\textit  {Prevention}~scenario:} Frequencies of resistance profiles (colours) over time during the \textit  {prevention}~scenario. The dots show the experimental measurements, and the error bar indicates the min/max interval between the replicates. The dash-dotted line shows the mean value of 100 stochastic simulations based on the instruction set used in the in vitro experiment. The solid line represents the mean value of 100 simulations with randomly created instruction sets based on the parameter set used in the experiment. The shaded error band indicates the 95-percentile interval between the simulations.\relax }}{43}{\textbf {\textit {Prevention}~scenario:} Frequencies of resistance profiles (colours) over time during the \textit {prevention}~scenario. The dots show the experimental measurements, and the error bar indicates the min/max interval between the replicates. The dash-dotted line shows the mean value of 100 stochastic simulations based on the instruction set used in the in vitro experiment. The solid line represents the mean value of 100 simulations with randomly created instruction sets based on the parameter set used in the experiment. The shaded error band indicates the 95-percentile interval between the simulations.\relax }{figure.caption.60}{}}
\newlabel{fig:stoch_exp}{{\M@TitleReference {2.7a}{\relax }}{44}{\relax }{figure.caption.61}{}}
\newlabel{sub@fig:stoch_exp}{{\M@TitleReference {a}{\relax }}{44}{\relax }{figure.caption.61}{}}
\newlabel{fig:stoch_val}{{\M@TitleReference {2.7b}{\relax }}{44}{\relax }{figure.caption.61}{}}
\newlabel{sub@fig:stoch_val}{{\M@TitleReference {b}{\relax }}{44}{\relax }{figure.caption.61}{}}
\newlabel{fig:stoch_var}{{\M@TitleReference {2.7c}{\relax }}{44}{\relax }{figure.caption.61}{}}
\newlabel{sub@fig:stoch_var}{{\M@TitleReference {c}{\relax }}{44}{\relax }{figure.caption.61}{}}
\newlabel{fig:stoch_par}{{\M@TitleReference {2.7d}{\relax }}{44}{\relax }{figure.caption.61}{}}
\newlabel{sub@fig:stoch_par}{{\M@TitleReference {d}{\relax }}{44}{\relax }{figure.caption.61}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.7}{\ignorespaces Illustration depicting the various sources of stochasticity and variation in experiments and simulations. Our experiments and simulations investigate various sources of stochasticity and their contributions to the variability of the outcome. In panels \textbf  {A}-\textbf  {D}, we sketch the different sources of stochasticity for each experiment and simulation, highlighting our primary focus in red. \textbf  {(A) \textit  {In vitro} Experiment.} Each experiment explores a scenario and is defined by a distinct parameter set (\textit  {prevention} (P), \textit  {containment} (C), \textit  {maximum emergence} (E)). We randomly generated one instruction set for each parameter set~$i$: \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}z^{1}}. For each instruction set \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}z^{1}}, we replicated the cumulative in-well dynamics four times \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}r^{1}_{j}}. \textbf  {(B) Validation Simulation.} To assess our computational model, we employed identical parameter sets and instruction sets \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}z^{1}}, as employed in the \textit  {in vitro} experiments. For each instruction set \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}z^{1}}, we conducted 100 stochastic simulations \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}s^{1}_{j}}. \textbf  {(C) Variation Simulation.} For every \textit  {in vitro} parameter set, we randomly generated 100 alternative instruction sets \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}z^{k}} to quantify the influence of experimental decisions on the experiment's outcomes. For each instruction set, we performed one simulation \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}s^{k}_{1}}. \textbf  {(D) \textit  {In Silico} Sensitivity Analysis.} We examined the sensitivity of our experimental findings to the input parameters by examining the effects of varying the input parameters on the resulting frequency of uninfected cases for different treatment strategies. To achieve this, we generated 20{,}000 alternative parameter sets \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}p}. We created ten randomised instruction sets \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}z^{k}} for each parameter set~\ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}p} and simulated each instruction set one time (\ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}s^{k}_{1}}).\relax }}{44}{figure.caption.61}\protected@file@percent }
\newlabel{fig:stochs}{{\M@TitleReference {2.7}{Illustration depicting the various sources of stochasticity and variation in experiments and simulations. Our experiments and simulations investigate various sources of stochasticity and their contributions to the variability of the outcome. In panels \textbf  {A}-\textbf  {D}, we sketch the different sources of stochasticity for each experiment and simulation, highlighting our primary focus in red. \textbf  {(A) \textit  {In vitro} Experiment.} Each experiment explores a scenario and is defined by a distinct parameter set (\textit  {prevention} (P), \textit  {containment} (C), \textit  {maximum emergence} (E)). We randomly generated one instruction set for each parameter set~$i$: \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}z^{1}}. For each instruction set \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}z^{1}}, we replicated the cumulative in-well dynamics four times \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}r^{1}_{j}}. \textbf  {(B) Validation Simulation.} To assess our computational model, we employed identical parameter sets and instruction sets \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}z^{1}}, as employed in the \textit  {in vitro} experiments. For each instruction set \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}z^{1}}, we conducted 100 stochastic simulations \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}s^{1}_{j}}. \textbf  {(C) Variation Simulation.} For every \textit  {in vitro} parameter set, we randomly generated 100 alternative instruction sets \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}z^{k}} to quantify the influence of experimental decisions on the experiment's outcomes. For each instruction set, we performed one simulation \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}s^{k}_{1}}. \textbf  {(D) \textit  {In Silico} Sensitivity Analysis.} We examined the sensitivity of our experimental findings to the input parameters by examining the effects of varying the input parameters on the resulting frequency of uninfected cases for different treatment strategies. To achieve this, we generated 20{,}000 alternative parameter sets \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}p}. We created ten randomised instruction sets \ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}z^{k}} for each parameter set~\ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}p} and simulated each instruction set one time (\ensuremath  {{}^{i}\tmspace  -\thinmuskip {.1667em}s^{k}_{1}}).\relax }}{44}{Illustration depicting the various sources of stochasticity and variation in experiments and simulations. Our experiments and simulations investigate various sources of stochasticity and their contributions to the variability of the outcome. In panels \textbf {A}-\textbf {D}, we sketch the different sources of stochasticity for each experiment and simulation, highlighting our primary focus in red. \textbf {(A) \textit {In vitro} Experiment.} Each experiment explores a scenario and is defined by a distinct parameter set (\textit {prevention} (P), \textit {containment} (C), \textit {maximum emergence} (E)). We randomly generated one instruction set for each parameter set~$i$: \ensuremath {{}^{i}\!z^{1}}. For each instruction set \ensuremath {{}^{i}\!z^{1}}, we replicated the cumulative in-well dynamics four times \ensuremath {{}^{i}\!r^{1}_{j}}. \textbf {(B) Validation Simulation.} To assess our computational model, we employed identical parameter sets and instruction sets \ensuremath {{}^{i}\!z^{1}}, as employed in the \textit {in vitro} experiments. For each instruction set \ensuremath {{}^{i}\!z^{1}}, we conducted 100 stochastic simulations \ensuremath {{}^{i}\!s^{1}_{j}}. \textbf {(C) Variation Simulation.} For every \textit {in vitro} parameter set, we randomly generated 100 alternative instruction sets \ensuremath {{}^{i}\!z^{k}} to quantify the influence of experimental decisions on the experiment's outcomes. For each instruction set, we performed one simulation \ensuremath {{}^{i}\!s^{k}_{1}}. \textbf {(D) \textit {In Silico} Sensitivity Analysis.} We examined the sensitivity of our experimental findings to the input parameters by examining the effects of varying the input parameters on the resulting frequency of uninfected cases for different treatment strategies. To achieve this, we generated 20{,}000 alternative parameter sets \ensuremath {{}^{i}\!p}. We created ten randomised instruction sets \ensuremath {{}^{i}\!z^{k}} for each parameter set~\ensuremath {{}^{i}\!p} and simulated each instruction set one time (\ensuremath {{}^{i}\!s^{k}_{1}}).\relax }{figure.caption.61}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.8}{\ignorespaces \textbf  {\textit  {Containment} scenario:} Frequencies of resistance profiles (colours) over time during the \textit  {containment}~scenario. The dots show the experimental measurements, and the error bar indicates the min/max interval between the replicates. The dash-dotted line shows the mean value of 100 stochastic simulations based on the instruction set used in the in vitro experiment. The solid line represents the mean value of 100 simulations with randomly created instruction sets based on the parameter set used in the experiment. The shaded error band indicates the 95-percentile interval between the simulations.\relax }}{45}{figure.caption.62}\protected@file@percent }
\newlabel{fig:exp2}{{\M@TitleReference {2.8}{\textbf  {\textit  {Containment} scenario:} Frequencies of resistance profiles (colours) over time during the \textit  {containment}~scenario. The dots show the experimental measurements, and the error bar indicates the min/max interval between the replicates. The dash-dotted line shows the mean value of 100 stochastic simulations based on the instruction set used in the in vitro experiment. The solid line represents the mean value of 100 simulations with randomly created instruction sets based on the parameter set used in the experiment. The shaded error band indicates the 95-percentile interval between the simulations.\relax }}{45}{\textbf {\textit {Containment} scenario:} Frequencies of resistance profiles (colours) over time during the \textit {containment}~scenario. The dots show the experimental measurements, and the error bar indicates the min/max interval between the replicates. The dash-dotted line shows the mean value of 100 stochastic simulations based on the instruction set used in the in vitro experiment. The solid line represents the mean value of 100 simulations with randomly created instruction sets based on the parameter set used in the experiment. The shaded error band indicates the 95-percentile interval between the simulations.\relax }{figure.caption.62}{}}
\newlabel{fig:BtreatAr}{{\M@TitleReference {2.9a}{\relax }}{46}{\relax }{figure.caption.63}{}}
\newlabel{sub@fig:BtreatAr}{{\M@TitleReference {a}{\relax }}{46}{\relax }{figure.caption.63}{}}
\newlabel{fig:phenotyping}{{\M@TitleReference {2.9b}{\relax }}{46}{\relax }{figure.caption.63}{}}
\newlabel{sub@fig:phenotyping}{{\M@TitleReference {b}{\relax }}{46}{\relax }{figure.caption.63}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.9}{\ignorespaces  \textbf  {(A)} Experimentally measured resistance profiles for 1784 wells with the pre-treatment profile \( A_r \) and treatment with drug B during the \textit  {maximum-emergence}~scenario. \textbf  {(B)} Decision tree to calculate the distribution of measured phenotypes for a well that contains \( Z_\emptyset \) sensitive and \( Z_A \) A-resistant bacteria. $g_\mitvartheta $ is the probability of drawing a drop that forms a colony on a plate treated with drug $\mitvartheta $, while $g_\mitvartheta '$ is the probability that it does not form a colony. \relax }}{46}{figure.caption.63}\protected@file@percent }
\@writefile{lof}{\contentsline {figure}{\numberline {2.10}{\ignorespaces  Maximum growth rates of sensitive and plasmid-carrying strains, measured using OD-growth curves. Each dot represents an individual well, and vertical bars indicate the mean. The sensitive strain was used as the reference ("ref") for pairwise comparisons to the plasmid-carrying strains to identify potential plasmid costs. We used the Mann-Whitney U tests with the Bonferroni correction to identify significant differences in growth rates. All pairwise comparisons were not significant (n.s.). \relax }}{47}{figure.caption.64}\protected@file@percent }
\newlabel{fig:plasmid_costs}{{\M@TitleReference {2.10}{ Maximum growth rates of sensitive and plasmid-carrying strains, measured using OD-growth curves. Each dot represents an individual well, and vertical bars indicate the mean. The sensitive strain was used as the reference ("ref") for pairwise comparisons to the plasmid-carrying strains to identify potential plasmid costs. We used the Mann-Whitney U tests with the Bonferroni correction to identify significant differences in growth rates. All pairwise comparisons were not significant (n.s.). \relax }}{47}{ Maximum growth rates of sensitive and plasmid-carrying strains, measured using OD-growth curves. Each dot represents an individual well, and vertical bars indicate the mean. The sensitive strain was used as the reference ("ref") for pairwise comparisons to the plasmid-carrying strains to identify potential plasmid costs. We used the Mann-Whitney U tests with the Bonferroni correction to identify significant differences in growth rates. All pairwise comparisons were not significant (n.s.). \relax }{figure.caption.64}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.11}{\ignorespaces \textbf  {\textit  {Prevention}~scenario with filtered transition probabilities.} Frequencies of resistance profiles (colours) over time during the \textit  {prevention} scenario. The dots show the experimental measurements, and the error bar indicates the min/max interval between the replicates. The dash-dotted line shows the mean value of 100 stochastic simulations based on the instruction set used in the in vitro experiment. The solid line represents the mean value of 100 simulations with randomly created instruction sets based on the parameter set used in the experiment. The shaded error band indicates the 95-percentile interval between the simulations.\relax }}{48}{figure.caption.65}\protected@file@percent }
\newlabel{fig:exp1_filtered}{{\M@TitleReference {2.11}{\textbf  {\textit  {Prevention}~scenario with filtered transition probabilities.} Frequencies of resistance profiles (colours) over time during the \textit  {prevention} scenario. The dots show the experimental measurements, and the error bar indicates the min/max interval between the replicates. The dash-dotted line shows the mean value of 100 stochastic simulations based on the instruction set used in the in vitro experiment. The solid line represents the mean value of 100 simulations with randomly created instruction sets based on the parameter set used in the experiment. The shaded error band indicates the 95-percentile interval between the simulations.\relax }}{48}{\textbf {\textit {Prevention}~scenario with filtered transition probabilities.} Frequencies of resistance profiles (colours) over time during the \textit {prevention} scenario. The dots show the experimental measurements, and the error bar indicates the min/max interval between the replicates. The dash-dotted line shows the mean value of 100 stochastic simulations based on the instruction set used in the in vitro experiment. The solid line represents the mean value of 100 simulations with randomly created instruction sets based on the parameter set used in the experiment. The shaded error band indicates the 95-percentile interval between the simulations.\relax }{figure.caption.65}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.12}{\ignorespaces  Sensitivity analysis using filtered transition probabilities. We evaluated the effectiveness of the five treatment strategies in maximising the frequency of uninfected \textit  {in silico} patients across randomly generated parameter sets. Strategies not significantly better than any other are marked as losers (pastel red), with those significantly worse than all others being labelled as single losers (dark red). Conversely, strategies that are not significantly worse than any other are classified as winners (pastel blue), and those significantly better than all others as single winners (dark blue). \textbf  {(A)} Evaluation of 10,000 parameter sets with preexisting double resistance. 659 out of 10,000 parameter sets yielded no significant difference between the strategies. \textbf  {(B)} Evaluation of 10,000 parameter sets without preexisting double resistance. 8 out of 10,000 parameter sets yielded no significant difference between the strategies. \relax }}{49}{figure.caption.66}\protected@file@percent }
\newlabel{fig:senstivity_clean}{{\M@TitleReference {2.12}{ Sensitivity analysis using filtered transition probabilities. We evaluated the effectiveness of the five treatment strategies in maximising the frequency of uninfected \textit  {in silico} patients across randomly generated parameter sets. Strategies not significantly better than any other are marked as losers (pastel red), with those significantly worse than all others being labelled as single losers (dark red). Conversely, strategies that are not significantly worse than any other are classified as winners (pastel blue), and those significantly better than all others as single winners (dark blue). \textbf  {(A)} Evaluation of 10,000 parameter sets with preexisting double resistance. 659 out of 10,000 parameter sets yielded no significant difference between the strategies. \textbf  {(B)} Evaluation of 10,000 parameter sets without preexisting double resistance. 8 out of 10,000 parameter sets yielded no significant difference between the strategies. \relax }}{49}{ Sensitivity analysis using filtered transition probabilities. We evaluated the effectiveness of the five treatment strategies in maximising the frequency of uninfected \textit {in silico} patients across randomly generated parameter sets. Strategies not significantly better than any other are marked as losers (pastel red), with those significantly worse than all others being labelled as single losers (dark red). Conversely, strategies that are not significantly worse than any other are classified as winners (pastel blue), and those significantly better than all others as single winners (dark blue). \textbf {(A)} Evaluation of 10,000 parameter sets with preexisting double resistance. 659 out of 10,000 parameter sets yielded no significant difference between the strategies. \textbf {(B)} Evaluation of 10,000 parameter sets without preexisting double resistance. 8 out of 10,000 parameter sets yielded no significant difference between the strategies. \relax }{figure.caption.66}{}}
\abx@aux@cite{Feher2012}
\abx@aux@segm{4}{0}{Feher2012}
\abx@aux@cite{Huisman2022}
\abx@aux@segm{4}{0}{Huisman2022}
\abx@aux@cite{Huisman2022}
\abx@aux@segm{4}{0}{Huisman2022}
\abx@aux@cite{Huisman2022}
\abx@aux@segm{4}{0}{Huisman2022}
\@writefile{lot}{\contentsline {table}{\numberline {2.2}{\ignorespaces Number of superinfections ($N_{\symcal S}$) between high- and low-concentrated $A_r$ and $B_r$ wells and the number of double resistances that emerged ($N_{\symcal E}$) under treatment $\mitvartheta $ across all three experiments.\relax }}{50}{table.caption.67}\protected@file@percent }
\newlabel{tab:encounter_advanced}{{\M@TitleReference {2.2}{Number of superinfections ($N_{\symcal S}$) between high- and low-concentrated $A_r$ and $B_r$ wells and the number of double resistances that emerged ($N_{\symcal E}$) under treatment $\mitvartheta $ across all three experiments.\relax }}{50}{Number of superinfections ($N_{\mathcal S}$) between high- and low-concentrated $A_r$ and $B_r$ wells and the number of double resistances that emerged ($N_{\mathcal E}$) under treatment $\vartheta $ across all three experiments.\relax }{table.caption.67}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.3}{\ignorespaces Strains used in this study and their relevant phenotypes. The phenotype in brackets is conferred by the respective plasmid. Cm\textsuperscript  {R}: Chloramphenicol resistance, Amp\textsuperscript  {R}: Ampicillin resistance, Caz\textsuperscript  {R}: Ceftazidime resistance, Tet\textsuperscript  {R}: Tetracycline resistance.\relax }}{50}{table.caption.68}\protected@file@percent }
\newlabel{tab:strainPhenotypes}{{\M@TitleReference {2.3}{Strains used in this study and their relevant phenotypes. The phenotype in brackets is conferred by the respective plasmid. Cm\textsuperscript  {R}: Chloramphenicol resistance, Amp\textsuperscript  {R}: Ampicillin resistance, Caz\textsuperscript  {R}: Ceftazidime resistance, Tet\textsuperscript  {R}: Tetracycline resistance.\relax }}{50}{Strains used in this study and their relevant phenotypes. The phenotype in brackets is conferred by the respective plasmid. Cm\textsuperscript {R}: Chloramphenicol resistance, Amp\textsuperscript {R}: Ampicillin resistance, Caz\textsuperscript {R}: Ceftazidime resistance, Tet\textsuperscript {R}: Tetracycline resistance.\relax }{table.caption.68}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.4}{\ignorespaces Statistical comparison of maximum growth rates between the sensitive and plasmid-carrying strains. We used a Mann-Whitney U test for pairwise comparisons, and the p-values were adjusted using the Bonferroni correction. \relax }}{50}{table.caption.69}\protected@file@percent }
\newlabel{tab:man_ferroni}{{\M@TitleReference {2.4}{Statistical comparison of maximum growth rates between the sensitive and plasmid-carrying strains. We used a Mann-Whitney U test for pairwise comparisons, and the p-values were adjusted using the Bonferroni correction. \relax }}{50}{Statistical comparison of maximum growth rates between the sensitive and plasmid-carrying strains. We used a Mann-Whitney U test for pairwise comparisons, and the p-values were adjusted using the Bonferroni correction. \relax }{table.caption.69}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.5}{\ignorespaces  Plasmid segregation loss was estimated over 24 hours without treatment and with selective treatment as a control. Frequencies of plasmid retention were compared between $t_0$ -- $t_1$ using the Mann-Whitney~U test. Confidence intervals and the mean frequencies were estimated by bootstrapping the binary data (plasmid retained or lost) pooled across replicates. No significant plasmid loss was observed in either the main data or the control. \relax }}{51}{table.caption.70}\protected@file@percent }
\newlabel{tab:loss_data}{{\M@TitleReference {2.5}{ Plasmid segregation loss was estimated over 24 hours without treatment and with selective treatment as a control. Frequencies of plasmid retention were compared between $t_0$ -- $t_1$ using the Mann-Whitney~U test. Confidence intervals and the mean frequencies were estimated by bootstrapping the binary data (plasmid retained or lost) pooled across replicates. No significant plasmid loss was observed in either the main data or the control. \relax }}{51}{ Plasmid segregation loss was estimated over 24 hours without treatment and with selective treatment as a control. Frequencies of plasmid retention were compared between $t_0$ -- $t_1$ using the Mann-Whitney~U test. Confidence intervals and the mean frequencies were estimated by bootstrapping the binary data (plasmid retained or lost) pooled across replicates. No significant plasmid loss was observed in either the main data or the control. \relax }{table.caption.70}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.6}{\ignorespaces 95 \% confidence intervals for the final bacterial density measured by colony plating and the maximal growth rates measured by evaluating OD-growth curves.\relax }}{51}{table.caption.71}\protected@file@percent }
\newlabel{tab:growth_and_density}{{\M@TitleReference {2.6}{95 \% confidence intervals for the final bacterial density measured by colony plating and the maximal growth rates measured by evaluating OD-growth curves.\relax }}{51}{95 \% confidence intervals for the final bacterial density measured by colony plating and the maximal growth rates measured by evaluating OD-growth curves.\relax }{table.caption.71}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.7}{\ignorespaces Definition of resistance profiles (rows) by growth patterns on differently treated \textit  {agar plates} (columns). X indicates colony formation, whereas o indicates no growth.\relax }}{51}{table.caption.72}\protected@file@percent }
\newlabel{tab:phenotyping}{{\M@TitleReference {2.7}{Definition of resistance profiles (rows) by growth patterns on differently treated \textit  {agar plates} (columns). X indicates colony formation, whereas o indicates no growth.\relax }}{51}{Definition of resistance profiles (rows) by growth patterns on differently treated \textit {agar plates} (columns). X indicates colony formation, whereas o indicates no growth.\relax }{table.caption.72}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.8}{\ignorespaces Association between bacterial phenotypes (rows) and resistance profiles \(\mitphi \) (columns). An 'X' denotes that a phenotype is obligatory for a given profile, while a '\(\surd \)' indicates that it is optional. \relax }}{52}{table.caption.73}\protected@file@percent }
\newlabel{tab:bacterial-phenotypes}{{\M@TitleReference {2.8}{Association between bacterial phenotypes (rows) and resistance profiles \(\mitphi \) (columns). An 'X' denotes that a phenotype is obligatory for a given profile, while a '\(\surd \)' indicates that it is optional. \relax }}{52}{Association between bacterial phenotypes (rows) and resistance profiles \(\phi \) (columns). An 'X' denotes that a phenotype is obligatory for a given profile, while a '\(\surd \)' indicates that it is optional. \relax }{table.caption.73}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.9}{\ignorespaces Clearance probability of well phenotypes across the three experiments.\relax }}{52}{table.caption.74}\protected@file@percent }
\newlabel{tab:clearance}{{\M@TitleReference {2.9}{Clearance probability of well phenotypes across the three experiments.\relax }}{52}{Clearance probability of well phenotypes across the three experiments.\relax }{table.caption.74}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.10}{\ignorespaces \textbf  {Mixing rules.} During the platehandling phase, we mix wells due to infections. The resulting phenotype of the two mixed wells can be calculated using this table. More than two phenotypes can be combined by applying associative logic. \relax }}{52}{table.caption.75}\protected@file@percent }
\newlabel{tab:mixing_rules}{{\M@TitleReference {2.10}{\textbf  {Mixing rules.} During the platehandling phase, we mix wells due to infections. The resulting phenotype of the two mixed wells can be calculated using this table. More than two phenotypes can be combined by applying associative logic. \relax }}{52}{\textbf {Mixing rules.} During the platehandling phase, we mix wells due to infections. The resulting phenotype of the two mixed wells can be calculated using this table. More than two phenotypes can be combined by applying associative logic. \relax }{table.caption.75}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.11}{\ignorespaces Mean parameter leading to $n$ single wins during the sensitivity analysis without preexisting double resistance. Strategies that did not yield at least one single win were excluded.\relax }}{53}{table.caption.76}\protected@file@percent }
\newlabel{tab:best_stats_no_preex}{{\M@TitleReference {2.11}{Mean parameter leading to $n$ single wins during the sensitivity analysis without preexisting double resistance. Strategies that did not yield at least one single win were excluded.\relax }}{53}{Mean parameter leading to $n$ single wins during the sensitivity analysis without preexisting double resistance. Strategies that did not yield at least one single win were excluded.\relax }{table.caption.76}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.12}{\ignorespaces Mean parameter leading to $n$ single losses during the sensitivity analysis without preexisting double resistance. Strategies that did not yield at least one single loss were excluded.\relax }}{53}{table.caption.76}\protected@file@percent }
\newlabel{tab:worst_stats_no_preex}{{\M@TitleReference {2.12}{Mean parameter leading to $n$ single losses during the sensitivity analysis without preexisting double resistance. Strategies that did not yield at least one single loss were excluded.\relax }}{53}{Mean parameter leading to $n$ single losses during the sensitivity analysis without preexisting double resistance. Strategies that did not yield at least one single loss were excluded.\relax }{table.caption.76}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.13}{\ignorespaces Mean parameter leading to $n$ single wins during the sensitivity analysis with preexisting double resistance. Strategies that did not yield at least one single win were excluded.\relax }}{53}{table.caption.76}\protected@file@percent }
\newlabel{tab:best_stats_preexisting}{{\M@TitleReference {2.13}{Mean parameter leading to $n$ single wins during the sensitivity analysis with preexisting double resistance. Strategies that did not yield at least one single win were excluded.\relax }}{53}{Mean parameter leading to $n$ single wins during the sensitivity analysis with preexisting double resistance. Strategies that did not yield at least one single win were excluded.\relax }{table.caption.76}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.14}{\ignorespaces Mean parameter leading to $n$ single losses during the sensitivity analysis with preexisting double resistance. Strategies that did not yield at least one single loss were excluded.\relax }}{53}{table.caption.76}\protected@file@percent }
\newlabel{tab:worst_stats_preexisting}{{\M@TitleReference {2.14}{Mean parameter leading to $n$ single losses during the sensitivity analysis with preexisting double resistance. Strategies that did not yield at least one single loss were excluded.\relax }}{53}{Mean parameter leading to $n$ single losses during the sensitivity analysis with preexisting double resistance. Strategies that did not yield at least one single loss were excluded.\relax }{table.caption.76}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.15}{\ignorespaces Wins and losses during the sensitivity analysis. With preexisting double resistance. 606 parameter sets yielded an insignificant result.\relax }}{54}{table.caption.77}\protected@file@percent }
\newlabel{tab:win_loss_statistic_preex}{{\M@TitleReference {2.15}{Wins and losses during the sensitivity analysis. With preexisting double resistance. 606 parameter sets yielded an insignificant result.\relax }}{54}{Wins and losses during the sensitivity analysis. With preexisting double resistance. 606 parameter sets yielded an insignificant result.\relax }{table.caption.77}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.16}{\ignorespaces Wins and losses during the sensitivity analysis without preexisting double resistance. 100 parameter sets yielded an insignificant result.\relax }}{54}{table.caption.77}\protected@file@percent }
\newlabel{tab:win_loss_statistic_no_preex}{{\M@TitleReference {2.16}{Wins and losses during the sensitivity analysis without preexisting double resistance. 100 parameter sets yielded an insignificant result.\relax }}{54}{Wins and losses during the sensitivity analysis without preexisting double resistance. 100 parameter sets yielded an insignificant result.\relax }{table.caption.77}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.17}{\ignorespaces Wins and losses during the sensitivity analysis, using filtered transition probabilities and preexisting double resistance. 659 parameter sets yielded an insignificant result.\relax }}{54}{table.caption.77}\protected@file@percent }
\newlabel{tab:win_loss_statistic_clean_preexisting}{{\M@TitleReference {2.17}{Wins and losses during the sensitivity analysis, using filtered transition probabilities and preexisting double resistance. 659 parameter sets yielded an insignificant result.\relax }}{54}{Wins and losses during the sensitivity analysis, using filtered transition probabilities and preexisting double resistance. 659 parameter sets yielded an insignificant result.\relax }{table.caption.77}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.18}{\ignorespaces Wins and losses during the sensitivity analysis with filtered transition matrices and no preexisting double resistance. 8 parameter sets yielded an insignificant result.\relax }}{54}{table.caption.77}\protected@file@percent }
\newlabel{tab:win_loss_statistic_clean_no_preex}{{\M@TitleReference {2.18}{Wins and losses during the sensitivity analysis with filtered transition matrices and no preexisting double resistance. 8 parameter sets yielded an insignificant result.\relax }}{54}{Wins and losses during the sensitivity analysis with filtered transition matrices and no preexisting double resistance. 8 parameter sets yielded an insignificant result.\relax }{table.caption.77}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.19}{\ignorespaces $M^{\mathrm {none}}$. Unfiltered transition matrix for untreated wells.\relax }}{55}{table.caption.78}\protected@file@percent }
\newlabel{tab:m_none}{{\M@TitleReference {2.19}{$M^{\mathrm {none}}$. Unfiltered transition matrix for untreated wells.\relax }}{55}{$M^{\mathrm {none}}$. Unfiltered transition matrix for untreated wells.\relax }{table.caption.78}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.20}{\ignorespaces $M^{\mathrm {A}}$. Unfiltered transition matrix for wells treated with antibiotic A.\relax }}{55}{table.caption.78}\protected@file@percent }
\newlabel{tab:m_a}{{\M@TitleReference {2.20}{$M^{\mathrm {A}}$. Unfiltered transition matrix for wells treated with antibiotic A.\relax }}{55}{$M^{\mathrm {A}}$. Unfiltered transition matrix for wells treated with antibiotic A.\relax }{table.caption.78}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.21}{\ignorespaces $M^{\mathrm {B}}$. Unfiltered transition matrix for wells treated with antibiotic B.\relax }}{55}{table.caption.79}\protected@file@percent }
\newlabel{tab:m_b}{{\M@TitleReference {2.21}{$M^{\mathrm {B}}$. Unfiltered transition matrix for wells treated with antibiotic B.\relax }}{55}{$M^{\mathrm {B}}$. Unfiltered transition matrix for wells treated with antibiotic B.\relax }{table.caption.79}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.22}{\ignorespaces $M^{\mathrm {AB}}$. Unfiltered transition matrix for wells treated with antibiotic AB.\relax }}{55}{table.caption.79}\protected@file@percent }
\newlabel{tab:m_ab}{{\M@TitleReference {2.22}{$M^{\mathrm {AB}}$. Unfiltered transition matrix for wells treated with antibiotic AB.\relax }}{55}{$M^{\mathrm {AB}}$. Unfiltered transition matrix for wells treated with antibiotic AB.\relax }{table.caption.79}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.23}{\ignorespaces $M_1^{\mathrm {none}}$. Unfiltered transition matrix for the first time point in untreated wells.\relax }}{55}{table.caption.80}\protected@file@percent }
\newlabel{tab:m1_none}{{\M@TitleReference {2.23}{$M_1^{\mathrm {none}}$. Unfiltered transition matrix for the first time point in untreated wells.\relax }}{55}{$M_1^{\mathrm {none}}$. Unfiltered transition matrix for the first time point in untreated wells.\relax }{table.caption.80}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.24}{\ignorespaces $M_1^{\mathrm {A}}$. Unfiltered transition matrix for the first time point in wells treated with antibiotic A.\relax }}{55}{table.caption.80}\protected@file@percent }
\newlabel{tab:m1_a}{{\M@TitleReference {2.24}{$M_1^{\mathrm {A}}$. Unfiltered transition matrix for the first time point in wells treated with antibiotic A.\relax }}{55}{$M_1^{\mathrm {A}}$. Unfiltered transition matrix for the first time point in wells treated with antibiotic A.\relax }{table.caption.80}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.25}{\ignorespaces $M_1^{\mathrm {B}}$. Unfiltered transition matrix for the first time point in wells treated with antibiotic B.\relax }}{56}{table.caption.81}\protected@file@percent }
\newlabel{tab:m1_b}{{\M@TitleReference {2.25}{$M_1^{\mathrm {B}}$. Unfiltered transition matrix for the first time point in wells treated with antibiotic B.\relax }}{56}{$M_1^{\mathrm {B}}$. Unfiltered transition matrix for the first time point in wells treated with antibiotic B.\relax }{table.caption.81}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.26}{\ignorespaces $M_1^{\mathrm {AB}}$. Unfiltered transition matrix for the first time point in wells treated with antibiotic AB.\relax }}{56}{table.caption.81}\protected@file@percent }
\newlabel{tab:m1_ab}{{\M@TitleReference {2.26}{$M_1^{\mathrm {AB}}$. Unfiltered transition matrix for the first time point in wells treated with antibiotic AB.\relax }}{56}{$M_1^{\mathrm {AB}}$. Unfiltered transition matrix for the first time point in wells treated with antibiotic AB.\relax }{table.caption.81}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.27}{\ignorespaces $M^{\mathrm {none}}$. Filtered transition matrix for untreated wells.\relax }}{56}{table.caption.82}\protected@file@percent }
\newlabel{tab:m_none_clean}{{\M@TitleReference {2.27}{$M^{\mathrm {none}}$. Filtered transition matrix for untreated wells.\relax }}{56}{$M^{\mathrm {none}}$. Filtered transition matrix for untreated wells.\relax }{table.caption.82}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.28}{\ignorespaces $M^{\mathrm {A}}$. Filtered transition matrix for wells treated with antibiotic A.\relax }}{56}{table.caption.82}\protected@file@percent }
\newlabel{tab:m_a_clean}{{\M@TitleReference {2.28}{$M^{\mathrm {A}}$. Filtered transition matrix for wells treated with antibiotic A.\relax }}{56}{$M^{\mathrm {A}}$. Filtered transition matrix for wells treated with antibiotic A.\relax }{table.caption.82}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.29}{\ignorespaces $M^{\mathrm {B}}$. Filtered transition matrix for wells treated with antibiotic B.\relax }}{56}{table.caption.83}\protected@file@percent }
\newlabel{tab:m_b_clean}{{\M@TitleReference {2.29}{$M^{\mathrm {B}}$. Filtered transition matrix for wells treated with antibiotic B.\relax }}{56}{$M^{\mathrm {B}}$. Filtered transition matrix for wells treated with antibiotic B.\relax }{table.caption.83}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.30}{\ignorespaces $M^{\mathrm {AB}}$. Filtered transition matrix for wells treated with antibiotic AB.\relax }}{56}{table.caption.83}\protected@file@percent }
\newlabel{tab:m_ab_clean}{{\M@TitleReference {2.30}{$M^{\mathrm {AB}}$. Filtered transition matrix for wells treated with antibiotic AB.\relax }}{56}{$M^{\mathrm {AB}}$. Filtered transition matrix for wells treated with antibiotic AB.\relax }{table.caption.83}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.31}{\ignorespaces $M_1^{\mathrm {none}}$. Filtered transition matrix for the first time point in untreated wells.\relax }}{57}{table.caption.84}\protected@file@percent }
\newlabel{tab:m1_none_clean}{{\M@TitleReference {2.31}{$M_1^{\mathrm {none}}$. Filtered transition matrix for the first time point in untreated wells.\relax }}{57}{$M_1^{\mathrm {none}}$. Filtered transition matrix for the first time point in untreated wells.\relax }{table.caption.84}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.32}{\ignorespaces $M_1^{\mathrm {A}}$. Filtered transition matrix for the first time point in wells treated with antibiotic A.\relax }}{57}{table.caption.84}\protected@file@percent }
\newlabel{tab:m1_a_clean}{{\M@TitleReference {2.32}{$M_1^{\mathrm {A}}$. Filtered transition matrix for the first time point in wells treated with antibiotic A.\relax }}{57}{$M_1^{\mathrm {A}}$. Filtered transition matrix for the first time point in wells treated with antibiotic A.\relax }{table.caption.84}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.33}{\ignorespaces $M_1^{\mathrm {B}}$. Filtered transition matrix for the first time point in wells treated with antibiotic B.\relax }}{57}{table.caption.85}\protected@file@percent }
\newlabel{tab:m1_b_clean}{{\M@TitleReference {2.33}{$M_1^{\mathrm {B}}$. Filtered transition matrix for the first time point in wells treated with antibiotic B.\relax }}{57}{$M_1^{\mathrm {B}}$. Filtered transition matrix for the first time point in wells treated with antibiotic B.\relax }{table.caption.85}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.34}{\ignorespaces $M_1^{\mathrm {AB}}$. Filtered transition matrix for the first time point in wells treated with antibiotic AB.\relax }}{57}{table.caption.85}\protected@file@percent }
\newlabel{tab:m1_ab_clean}{{\M@TitleReference {2.34}{$M_1^{\mathrm {AB}}$. Filtered transition matrix for the first time point in wells treated with antibiotic AB.\relax }}{57}{$M_1^{\mathrm {AB}}$. Filtered transition matrix for the first time point in wells treated with antibiotic AB.\relax }{table.caption.85}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.35}{\ignorespaces \textit  {Prevention}~scenario: Effect of treatment strategies on the frequency of uninfecteds (ANOVA).\relax }}{57}{table.caption.86}\protected@file@percent }
\newlabel{tab:20210417U_anova}{{\M@TitleReference {2.35}{\textit  {Prevention}~scenario: Effect of treatment strategies on the frequency of uninfecteds (ANOVA).\relax }}{57}{\textit {Prevention}~scenario: Effect of treatment strategies on the frequency of uninfecteds (ANOVA).\relax }{table.caption.86}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.36}{\ignorespaces \textit  {Prevention}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of uninfecteds using Tukey's post-hoc analysis.\relax }}{58}{table.caption.87}\protected@file@percent }
\newlabel{tab:20210417U_tukey}{{\M@TitleReference {2.36}{\textit  {Prevention}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of uninfecteds using Tukey's post-hoc analysis.\relax }}{58}{\textit {Prevention}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of uninfecteds using Tukey's post-hoc analysis.\relax }{table.caption.87}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.37}{\ignorespaces \textit  {Prevention}~scenario: Effect of treatment strategies on the frequency of single resistance (ANOVA).\relax }}{58}{table.caption.88}\protected@file@percent }
\newlabel{tab:20210417single_anova}{{\M@TitleReference {2.37}{\textit  {Prevention}~scenario: Effect of treatment strategies on the frequency of single resistance (ANOVA).\relax }}{58}{\textit {Prevention}~scenario: Effect of treatment strategies on the frequency of single resistance (ANOVA).\relax }{table.caption.88}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.38}{\ignorespaces \textit  {Prevention}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of single resistance using Tukey's post-hoc analysis.\relax }}{59}{table.caption.89}\protected@file@percent }
\newlabel{tab:20210417single_tukey}{{\M@TitleReference {2.38}{\textit  {Prevention}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of single resistance using Tukey's post-hoc analysis.\relax }}{59}{\textit {Prevention}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of single resistance using Tukey's post-hoc analysis.\relax }{table.caption.89}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.39}{\ignorespaces \textit  {Prevention}~scenario: Effect of treatment strategies on the frequency of double resistance (ANOVA).\relax }}{59}{table.caption.90}\protected@file@percent }
\newlabel{tab:20210417double_anova}{{\M@TitleReference {2.39}{\textit  {Prevention}~scenario: Effect of treatment strategies on the frequency of double resistance (ANOVA).\relax }}{59}{\textit {Prevention}~scenario: Effect of treatment strategies on the frequency of double resistance (ANOVA).\relax }{table.caption.90}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.40}{\ignorespaces \textit  {Prevention}~scenario: Effect of treatment strategies on the frequency of double resistance (ANOVA).\relax }}{60}{table.caption.91}\protected@file@percent }
\newlabel{tab:20210417double_tukey}{{\M@TitleReference {2.40}{\textit  {Prevention}~scenario: Effect of treatment strategies on the frequency of double resistance (ANOVA).\relax }}{60}{\textit {Prevention}~scenario: Effect of treatment strategies on the frequency of double resistance (ANOVA).\relax }{table.caption.91}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.41}{\ignorespaces \textit  {Containment}~scenario: Effect of treatment strategies on the frequency of uninfecteds (ANOVA).\relax }}{60}{table.caption.92}\protected@file@percent }
\newlabel{tab:20220127U_anova}{{\M@TitleReference {2.41}{\textit  {Containment}~scenario: Effect of treatment strategies on the frequency of uninfecteds (ANOVA).\relax }}{60}{\textit {Containment}~scenario: Effect of treatment strategies on the frequency of uninfecteds (ANOVA).\relax }{table.caption.92}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.42}{\ignorespaces \textit  {Containment}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of uninfecteds using Tukey's post-hoc analysis.\relax }}{61}{table.caption.93}\protected@file@percent }
\newlabel{tab:20220127U_tukey}{{\M@TitleReference {2.42}{\textit  {Containment}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of uninfecteds using Tukey's post-hoc analysis.\relax }}{61}{\textit {Containment}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of uninfecteds using Tukey's post-hoc analysis.\relax }{table.caption.93}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.43}{\ignorespaces \textit  {Containment}~scenario: Effect of treatment strategies on the frequency of single resistance (ANOVA).\relax }}{61}{table.caption.94}\protected@file@percent }
\newlabel{tab:20220127single_anova}{{\M@TitleReference {2.43}{\textit  {Containment}~scenario: Effect of treatment strategies on the frequency of single resistance (ANOVA).\relax }}{61}{\textit {Containment}~scenario: Effect of treatment strategies on the frequency of single resistance (ANOVA).\relax }{table.caption.94}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.44}{\ignorespaces \textit  {Containment}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of single resistance using Tukey's post-hoc analysis.\relax }}{62}{table.caption.95}\protected@file@percent }
\newlabel{tab:20220127single_tukey}{{\M@TitleReference {2.44}{\textit  {Containment}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of single resistance using Tukey's post-hoc analysis.\relax }}{62}{\textit {Containment}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of single resistance using Tukey's post-hoc analysis.\relax }{table.caption.95}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.45}{\ignorespaces \textit  {Containment}~scenario: Effect of treatment strategies on the frequency of double resistance (ANOVA).\relax }}{62}{table.caption.96}\protected@file@percent }
\newlabel{tab:20220127double_anova}{{\M@TitleReference {2.45}{\textit  {Containment}~scenario: Effect of treatment strategies on the frequency of double resistance (ANOVA).\relax }}{62}{\textit {Containment}~scenario: Effect of treatment strategies on the frequency of double resistance (ANOVA).\relax }{table.caption.96}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.46}{\ignorespaces \textit  {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of uninfecteds (ANOVA).\relax }}{62}{table.caption.97}\protected@file@percent }
\newlabel{tab:20220412U_anova}{{\M@TitleReference {2.46}{\textit  {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of uninfecteds (ANOVA).\relax }}{62}{\textit {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of uninfecteds (ANOVA).\relax }{table.caption.97}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.47}{\ignorespaces \textit  {Maximum-emergence}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of uninfecteds using Tukey's post-hoc analysis.\relax }}{63}{table.caption.98}\protected@file@percent }
\newlabel{tab:20220412U_tukey}{{\M@TitleReference {2.47}{\textit  {Maximum-emergence}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of uninfecteds using Tukey's post-hoc analysis.\relax }}{63}{\textit {Maximum-emergence}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of uninfecteds using Tukey's post-hoc analysis.\relax }{table.caption.98}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.48}{\ignorespaces \textit  {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of single resistance (ANOVA).\relax }}{63}{table.caption.99}\protected@file@percent }
\newlabel{tab:20220412single_anova}{{\M@TitleReference {2.48}{\textit  {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of single resistance (ANOVA).\relax }}{63}{\textit {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of single resistance (ANOVA).\relax }{table.caption.99}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.49}{\ignorespaces \textit  {Maximum-emergence}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of single resistance using Tukey's post-hoc analysis.\relax }}{64}{table.caption.100}\protected@file@percent }
\newlabel{tab:20220412single_tukey}{{\M@TitleReference {2.49}{\textit  {Maximum-emergence}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of single resistance using Tukey's post-hoc analysis.\relax }}{64}{\textit {Maximum-emergence}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of single resistance using Tukey's post-hoc analysis.\relax }{table.caption.100}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.50}{\ignorespaces \textit  {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of double resistance (ANOVA).\relax }}{64}{table.caption.101}\protected@file@percent }
\newlabel{tab:20220412double_anova}{{\M@TitleReference {2.50}{\textit  {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of double resistance (ANOVA).\relax }}{64}{\textit {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of double resistance (ANOVA).\relax }{table.caption.101}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.51}{\ignorespaces \textit  {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of double resistance (ANOVA).\relax }}{65}{table.caption.102}\protected@file@percent }
\newlabel{tab:20220412double_tukey}{{\M@TitleReference {2.51}{\textit  {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of double resistance (ANOVA).\relax }}{65}{\textit {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of double resistance (ANOVA).\relax }{table.caption.102}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.52}{\ignorespaces \textit  {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of newly emerging double resistance (ANOVA).\relax }}{65}{table.caption.103}\protected@file@percent }
\newlabel{tab:emergence_anova}{{\M@TitleReference {2.52}{\textit  {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of newly emerging double resistance (ANOVA).\relax }}{65}{\textit {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of newly emerging double resistance (ANOVA).\relax }{table.caption.103}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.53}{\ignorespaces \textit  {Maximum-emergence}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of newly emerging double resistance using Tukey's post-hoc analysis.\relax }}{66}{table.caption.104}\protected@file@percent }
\newlabel{tab:emergence_tukey}{{\M@TitleReference {2.53}{\textit  {Maximum-emergence}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of newly emerging double resistance using Tukey's post-hoc analysis.\relax }}{66}{\textit {Maximum-emergence}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of newly emerging double resistance using Tukey's post-hoc analysis.\relax }{table.caption.104}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.54}{\ignorespaces \textit  {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of superinfections (ANOVA).\relax }}{66}{table.caption.105}\protected@file@percent }
\newlabel{tab:superinfection_anova}{{\M@TitleReference {2.54}{\textit  {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of superinfections (ANOVA).\relax }}{66}{\textit {Maximum-emergence}~scenario: Effect of treatment strategies on the frequency of superinfections (ANOVA).\relax }{table.caption.105}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.55}{\ignorespaces \textit  {Maximum-emergence}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of superinfections using Tukey's post-hoc analysis.\relax }}{67}{table.caption.106}\protected@file@percent }
\newlabel{tab:superinfection_tukey}{{\M@TitleReference {2.55}{\textit  {Maximum-emergence}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of superinfections using Tukey's post-hoc analysis.\relax }}{67}{\textit {Maximum-emergence}~scenario: Multiple comparison between the effects of treatment strategies on the frequencies of superinfections using Tukey's post-hoc analysis.\relax }{table.caption.106}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.56}{\ignorespaces \textit  {Maximum-emergence}~scenario: Effect of drug $\mitvartheta $ on the frequency of emergence per superinfection (ANOVA).\relax }}{67}{table.caption.107}\protected@file@percent }
\newlabel{tab:treatment_emergence_anova}{{\M@TitleReference {2.56}{\textit  {Maximum-emergence}~scenario: Effect of drug $\mitvartheta $ on the frequency of emergence per superinfection (ANOVA).\relax }}{67}{\textit {Maximum-emergence}~scenario: Effect of drug $\vartheta $ on the frequency of emergence per superinfection (ANOVA).\relax }{table.caption.107}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2.57}{\ignorespaces \textit  {Maximum-emergence}~scenario: Multiple comparison between the effects of drug $\mitvartheta $ on the frequencies of emergence per superinfection using Tukey's post-hoc analysis.\relax }}{67}{table.caption.108}\protected@file@percent }
\newlabel{tab:treatment_emergence_tukey}{{\M@TitleReference {2.57}{\textit  {Maximum-emergence}~scenario: Multiple comparison between the effects of drug $\mitvartheta $ on the frequencies of emergence per superinfection using Tukey's post-hoc analysis.\relax }}{67}{\textit {Maximum-emergence}~scenario: Multiple comparison between the effects of drug $\vartheta $ on the frequencies of emergence per superinfection using Tukey's post-hoc analysis.\relax }{table.caption.108}{}}
\abx@aux@refsection{5}{68}
\newlabel{refsection:5}{{\M@TitleReference {}{}}{68}{}{section*.109}{}}
\abx@aux@cite{Regoes2004}
\abx@aux@segm{5}{0}{Regoes2004}
\@writefile{lof}{\addvspace {10pt}}
\@writefile{lot}{\addvspace {10pt}}
\@writefile{toc}{\contentsline {chapter}{\chapternumberline {3}High-Throughput Quantification of Population Dynamics using Luminescence}{69}{chapter.3}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {3.1}abstract}{69}{section.3.1}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {3.2}Introduction}{69}{section.3.2}\protected@file@percent }
\abx@aux@cite{Regoes2004}
\abx@aux@segm{5}{0}{Regoes2004}
\abx@aux@cite{Foerster2016}
\abx@aux@segm{5}{0}{Foerster2016}
\abx@aux@cite{Vellend1977}
\abx@aux@segm{5}{0}{Vellend1977}
\abx@aux@cite{Jacobs1993}
\abx@aux@segm{5}{0}{Jacobs1993}
\abx@aux@cite{Loeliger2003}
\abx@aux@segm{5}{0}{Loeliger2003}
\abx@aux@cite{Engebrecht1985}
\abx@aux@segm{5}{0}{Engebrecht1985}
\abx@aux@cite{Meighen1991}
\abx@aux@segm{5}{0}{Meighen1991}
\abx@aux@cite{Kishony2003}
\abx@aux@segm{5}{0}{Kishony2003}
\abx@aux@cite{Yeh2006}
\abx@aux@segm{5}{0}{Yeh2006}
\abx@aux@cite{Chait2007}
\abx@aux@segm{5}{0}{Chait2007}
\abx@aux@cite{Larsson2014}
\abx@aux@segm{5}{0}{Larsson2014}
\abx@aux@cite{Kavcic2020}
\abx@aux@segm{5}{0}{Kavcic2020}
\abx@aux@cite{Angermayr2022}
\abx@aux@segm{5}{0}{Angermayr2022}
\abx@aux@cite{Salisbury1999}
\abx@aux@segm{5}{0}{Salisbury1999}
\abx@aux@cite{Beard2002}
\abx@aux@segm{5}{0}{Beard2002}
\abx@aux@cite{Alloush2003}
\abx@aux@segm{5}{0}{Alloush2003}
\abx@aux@cite{Kishony2003}
\abx@aux@segm{5}{0}{Kishony2003}
\@writefile{toc}{\contentsline {section}{\numberline {3.3}Results}{71}{section.3.3}\protected@file@percent }
\newlabel{fig:antibiotic_rates}{{\M@TitleReference {\caption@xref {fig:antibiotic_rates}{ on input line 16}}{Results}}{72}{Results}{figure.caption.110}{}}
\newlabel{sub@fig:antibiotic_rates}{{\M@TitleReference {}{Results}}{72}{Results}{figure.caption.110}{}}
\newlabel{fig:pexiganan_rates}{{\M@TitleReference {\caption@xref {fig:pexiganan_rates}{ on input line 23}}{Results}}{72}{Results}{figure.caption.110}{}}
\newlabel{sub@fig:pexiganan_rates}{{\M@TitleReference {}{Results}}{72}{Results}{figure.caption.110}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.1}{\ignorespaces  Comparison of CFU-based and luminescence-based rates of change. For each drug, we generated 2000 bootstrapped datasets by resampling timeseries CFU and lightintensity data with replacement and fitted an exponential function to each bootstrap replicate to obtain distributions of rates. Panel (a) shows these distributions for 20 drugconcentration assays across 19 antibiotics; panel (b) shows the antimicrobial peptide pexiganan at \SI {8}{\micro \gram \per \milli \liter } and \SI {16}{\micro \gram \per \milli \liter }. The distribution of $\mitpsi _{\mathrm {CFU}}$ is shown in blue (lower half of each violin, diamond). The distribution of $\mitpsi _{I}$ is shown in orange (upper half, triangle). Green distributions ($\mitpsi _{I}^*$; triangle) represent luminescencebased rates calculated from data starting at the first peak onward. Red distributions show volumeadjusted luminescence rates ($\mitpsi _{J}$; pentagon). Vertical lines mark the \SI {95}{\percent } confidence intervals. Asterisk (*) or letters (n.s.) indicate whether CFU-based rates differ significantly from the corresponding luminescence-based rate or not (see Methods), with color coding matching the respective luminescence-based distribution. Wide confidence intervals for pexiganan reflect biphasic killing, steep curves, and noisy CFU data. \relax }}{72}{figure.caption.110}\protected@file@percent }
\newlabel{fig:rate_plot}{{\M@TitleReference {3.1}{ Comparison of CFU-based and luminescence-based rates of change. For each drug, we generated 2000 bootstrapped datasets by resampling timeseries CFU and lightintensity data with replacement and fitted an exponential function to each bootstrap replicate to obtain distributions of rates. Panel (a) shows these distributions for 20 drugconcentration assays across 19 antibiotics; panel (b) shows the antimicrobial peptide pexiganan at \SI {8}{\micro \gram \per \milli \liter } and \SI {16}{\micro \gram \per \milli \liter }. The distribution of $\mitpsi _{\mathrm {CFU}}$ is shown in blue (lower half of each violin, diamond). The distribution of $\mitpsi _{I}$ is shown in orange (upper half, triangle). Green distributions ($\mitpsi _{I}^*$; triangle) represent luminescencebased rates calculated from data starting at the first peak onward. Red distributions show volumeadjusted luminescence rates ($\mitpsi _{J}$; pentagon). Vertical lines mark the \SI {95}{\percent } confidence intervals. Asterisk (*) or letters (n.s.) indicate whether CFU-based rates differ significantly from the corresponding luminescence-based rate or not (see Methods), with color coding matching the respective luminescence-based distribution. Wide confidence intervals for pexiganan reflect biphasic killing, steep curves, and noisy CFU data. \relax }}{72}{ Comparison of CFU-based and luminescence-based rates of change. For each drug, we generated 2000 bootstrapped datasets by resampling timeseries CFU and lightintensity data with replacement and fitted an exponential function to each bootstrap replicate to obtain distributions of rates. Panel (a) shows these distributions for 20 drugconcentration assays across 19 antibiotics; panel (b) shows the antimicrobial peptide pexiganan at \SI {8}{\micro \gram \per \milli \liter } and \SI {16}{\micro \gram \per \milli \liter }. The distribution of $\psi _{\mathrm {CFU}}$ is shown in blue (lower half of each violin, diamond). The distribution of $\psi _{I}$ is shown in orange (upper half, triangle). Green distributions ($\psi _{I}^*$; triangle) represent luminescencebased rates calculated from data starting at the first peak onward. Red distributions show volumeadjusted luminescence rates ($\psi _{J}$; pentagon). Vertical lines mark the \SI {95}{\percent } confidence intervals. Asterisk (*) or letters (n.s.) indicate whether CFU-based rates differ significantly from the corresponding luminescence-based rate or not (see Methods), with color coding matching the respective luminescence-based distribution. Wide confidence intervals for pexiganan reflect biphasic killing, steep curves, and noisy CFU data. \relax }{figure.caption.110}{}}
\@writefile{toc}{\contentsline {paragraph}{Light intensity is proportional to bacterial density.}{73}{section*.111}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Luminescence-based rates agree with CFU-based kill rates in 11 out of 22 antimicrobial assays.}{73}{section*.112}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{No support for SOS-driven increase in luminescence promoter activity.}{73}{section*.113}\protected@file@percent }
\abx@aux@cite{Wang2010}
\abx@aux@segm{5}{0}{Wang2010}
\@writefile{toc}{\contentsline {paragraph}{Filamentation aligns with divergence between CFU- and luminescence-based rates.}{74}{section*.114}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Filamentation model predicts divergence between luminescence- and CFU-based rates.}{74}{section*.116}\protected@file@percent }
\newlabel{fig:volume_pre}{{\M@TitleReference {\caption@xref {fig:volume_pre}{ on input line 92}}{Filamentation aligns with divergence between CFU- and luminescence-based rates.}}{75}{Filamentation aligns with divergence between CFU- and luminescence-based rates}{figure.caption.115}{}}
\newlabel{sub@fig:volume_pre}{{\M@TitleReference {}{Filamentation aligns with divergence between CFU- and luminescence-based rates.}}{75}{Filamentation aligns with divergence between CFU- and luminescence-based rates}{figure.caption.115}{}}
\newlabel{fig:volume_post}{{\M@TitleReference {\caption@xref {fig:volume_post}{ on input line 101}}{Filamentation aligns with divergence between CFU- and luminescence-based rates.}}{75}{Filamentation aligns with divergence between CFU- and luminescence-based rates}{figure.caption.115}{}}
\newlabel{sub@fig:volume_post}{{\M@TitleReference {}{Filamentation aligns with divergence between CFU- and luminescence-based rates.}}{75}{Filamentation aligns with divergence between CFU- and luminescence-based rates}{figure.caption.115}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.2}{\ignorespaces  Density distributions (2.5--97.5\% percentile range) of pooled cell volumes acquired by microscopy imaging, shown (a) before and (b) after 2 h of antibiotic treatment. Boxes indicate the 2575 \% interquartile range, and vertical bars mark the mean. Significance (*) was assessed by bootstrapping cell volumes 200 times with replacement for each replicate (image) and treatment, pooling the bootstrapped volumes by treatment, and comparing the resulting 95\% confidence interval of the mean to that of the untreated control (\texttt  {control\_2h}). \(\ddagger \) Carbapenems tend to deform cells into a lemon-like shape (\autoref  {fig:micro_mero}), resulting in poor fitting quality since our algorithm assumes a cylindrical geometry. \relax }}{75}{figure.caption.115}\protected@file@percent }
\newlabel{fig:volume_combined}{{\M@TitleReference {3.2}{ Density distributions (2.5--97.5\% percentile range) of pooled cell volumes acquired by microscopy imaging, shown (a) before and (b) after 2 h of antibiotic treatment. Boxes indicate the 2575 \% interquartile range, and vertical bars mark the mean. Significance (*) was assessed by bootstrapping cell volumes 200 times with replacement for each replicate (image) and treatment, pooling the bootstrapped volumes by treatment, and comparing the resulting 95\% confidence interval of the mean to that of the untreated control (\texttt  {control\_2h}). \(\ddagger \) Carbapenems tend to deform cells into a lemon-like shape (\autoref  {fig:micro_mero}), resulting in poor fitting quality since our algorithm assumes a cylindrical geometry. \relax }}{75}{ Density distributions (2.5--97.5\% percentile range) of pooled cell volumes acquired by microscopy imaging, shown (a) before and (b) after 2 h of antibiotic treatment. Boxes indicate the 2575 \% interquartile range, and vertical bars mark the mean. Significance (*) was assessed by bootstrapping cell volumes 200 times with replacement for each replicate (image) and treatment, pooling the bootstrapped volumes by treatment, and comparing the resulting 95\% confidence interval of the mean to that of the untreated control (\texttt {control\_2h}). \(\ddagger \) Carbapenems tend to deform cells into a lemon-like shape (\autoref {fig:micro_mero}), resulting in poor fitting quality since our algorithm assumes a cylindrical geometry. \relax }{figure.caption.115}{}}
\@writefile{toc}{\contentsline {paragraph}{Adjusting luminescence intensities by changes in volume narrows the gap between CFU- and luminescence-based rates.}{76}{section*.117}\protected@file@percent }
\abx@aux@cite{Eagle1949}
\abx@aux@segm{5}{0}{Eagle1949}
\abx@aux@cite{Besnard2002}
\abx@aux@segm{5}{0}{Besnard2002}
\abx@aux@cite{Oliver2005}
\abx@aux@segm{5}{0}{Oliver2005}
\abx@aux@cite{Li2014}
\abx@aux@segm{5}{0}{Li2014}
\@writefile{toc}{\contentsline {paragraph}{CFU-based estimates can overestimate the rate of population decline.}{77}{section*.119}\protected@file@percent }
\abx@aux@cite{Pearson1980}
\abx@aux@segm{5}{0}{Pearson1980}
\abx@aux@cite{Eng1991}
\abx@aux@segm{5}{0}{Eng1991}
\abx@aux@cite{Coates2018}
\abx@aux@segm{5}{0}{Coates2018}
\@writefile{lof}{\contentsline {figure}{\numberline {3.3}{\ignorespaces  Simulations based on the filamentation model quantifying how changes in division rate due to treatment ($\mitDelta \mitlambda $) and death rate ($\mitdelta $) influence the rate of change of population size ($\mitpsi _B$, blue), the rate of change of light intensity ($\mitpsi _I$, orange), and the rate of change of light intensity when the first 2 hours of data are excluded ($\mitpsi _{I}^*$, green). These illustrative simulations were conducted using an initial division rate $\mitlambda _0 = 1.5\tmspace  +\thinmuskip {.1667em}\mathrm {h}^{-1}$. More details and all parameter values can be found in \leavevmode {\color {blue}SI Appendix~3.3}.\relax }}{78}{figure.caption.118}\protected@file@percent }
\newlabel{fig:sensitivity}{{\M@TitleReference {3.3}{ Simulations based on the filamentation model quantifying how changes in division rate due to treatment ($\mitDelta \mitlambda $) and death rate ($\mitdelta $) influence the rate of change of population size ($\mitpsi _B$, blue), the rate of change of light intensity ($\mitpsi _I$, orange), and the rate of change of light intensity when the first 2 hours of data are excluded ($\mitpsi _{I}^*$, green). These illustrative simulations were conducted using an initial division rate $\mitlambda _0 = 1.5\tmspace  +\thinmuskip {.1667em}\mathrm {h}^{-1}$. More details and all parameter values can be found in \leavevmode {\color {blue}SI Appendix~3.3}.\relax }}{78}{ Simulations based on the filamentation model quantifying how changes in division rate due to treatment ($\Delta \lambda $) and death rate ($\delta $) influence the rate of change of population size ($\psi _B$, blue), the rate of change of light intensity ($\psi _I$, orange), and the rate of change of light intensity when the first 2 hours of data are excluded ($\psi _{I}^*$, green). These illustrative simulations were conducted using an initial division rate $\lambda _0 = 1.5\,\mathrm {h}^{-1}$. More details and all parameter values can be found in \siappendix {3}.\relax }{figure.caption.118}{}}
\abx@aux@cite{Salisbury1999}
\abx@aux@segm{5}{0}{Salisbury1999}
\abx@aux@cite{Marques2005}
\abx@aux@segm{5}{0}{Marques2005}
\abx@aux@cite{Levine1998}
\abx@aux@segm{5}{0}{Levine1998}
\abx@aux@cite{Besnard2002}
\abx@aux@segm{5}{0}{Besnard2002}
\abx@aux@cite{Wu2024}
\abx@aux@segm{5}{0}{Wu2024}
\abx@aux@cite{Fanous2025}
\abx@aux@segm{5}{0}{Fanous2025}
\abx@aux@cite{Gleckman1981}
\abx@aux@segm{5}{0}{Gleckman1981}
\@writefile{toc}{\contentsline {paragraph}{Partial loss of culturability causes CFU to underestimate \(\mitpsi _B\) for ciprofloxacin and trimethoprim treatment.}{79}{section*.120}\protected@file@percent }
\abx@aux@cite{Deslouches2005}
\abx@aux@segm{5}{0}{Deslouches2005}
\@writefile{toc}{\contentsline {paragraph}{Antimicrobial carryover causes underestimation of $\mitpsi _B$ for pexiganan using CFU.}{80}{section*.121}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Luminescence and CFU show identical decline rates for pexiganan time-kill curves if residual killing is prevented.}{81}{section*.122}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Pexiganan rapidly loses killing capacity.}{81}{section*.123}\protected@file@percent }
\abx@aux@cite{Eagle1949}
\abx@aux@segm{5}{0}{Eagle1949}
\abx@aux@cite{Baquero1986}
\abx@aux@segm{5}{0}{Baquero1986}
\abx@aux@cite{Besnard2002}
\abx@aux@segm{5}{0}{Besnard2002}
\abx@aux@cite{Oliver2005}
\abx@aux@segm{5}{0}{Oliver2005}
\abx@aux@cite{Li2014}
\abx@aux@segm{5}{0}{Li2014}
\abx@aux@cite{Wu2024}
\abx@aux@segm{5}{0}{Wu2024}
\abx@aux@cite{Pearson1980}
\abx@aux@segm{5}{0}{Pearson1980}
\abx@aux@cite{Eng1991}
\abx@aux@segm{5}{0}{Eng1991}
\abx@aux@cite{Coates2018}
\abx@aux@segm{5}{0}{Coates2018}
\abx@aux@cite{Deguchi2011}
\abx@aux@segm{5}{0}{Deguchi2011}
\@writefile{toc}{\contentsline {section}{\numberline {3.4}Discussion}{82}{section.3.4}\protected@file@percent }
\abx@aux@cite{Regoes2004}
\abx@aux@segm{5}{0}{Regoes2004}
\abx@aux@cite{Kishony2003}
\abx@aux@segm{5}{0}{Kishony2003}
\abx@aux@cite{Yeh2006}
\abx@aux@segm{5}{0}{Yeh2006}
\abx@aux@cite{Chait2007}
\abx@aux@segm{5}{0}{Chait2007}
\abx@aux@cite{Foerster2016}
\abx@aux@segm{5}{0}{Foerster2016}
\abx@aux@cite{Kavcic2020}
\abx@aux@segm{5}{0}{Kavcic2020}
\abx@aux@cite{Angermayr2022}
\abx@aux@segm{5}{0}{Angermayr2022}
\abx@aux@cite{Baquero1986}
\abx@aux@segm{5}{0}{Baquero1986}
\abx@aux@cite{Cayron2023}
\abx@aux@segm{5}{0}{Cayron2023}
\abx@aux@cite{Datsenko2000}
\abx@aux@segm{5}{0}{Datsenko2000}
\abx@aux@cite{Hughes2015}
\abx@aux@segm{5}{0}{Hughes2015}
\abx@aux@cite{Kishony2003}
\abx@aux@segm{5}{0}{Kishony2003}
\abx@aux@cite{Bjarnason2003}
\abx@aux@segm{5}{0}{Bjarnason2003}
\@writefile{toc}{\contentsline {section}{\numberline {3.5}Methods}{84}{section.3.5}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Strains.}{84}{section*.124}\protected@file@percent }
\abx@aux@cite{EUCAST2025}
\abx@aux@segm{5}{0}{EUCAST2025}
\abx@aux@cite{Jett1997}
\abx@aux@segm{5}{0}{Jett1997}
\@writefile{toc}{\contentsline {paragraph}{Media.}{85}{section*.125}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Automated CFU plating.}{85}{section*.126}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Luminescence measurements.}{85}{section*.127}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Luminescence-CFU assay setup.}{86}{section*.128}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Rapid luminescence-CFU assay setup.}{86}{section*.129}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Morphology experiments.}{86}{section*.130}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Fitting rates of change $\mitpsi $.}{86}{section*.131}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Significance.}{87}{section*.132}\protected@file@percent }
\abx@aux@refsection{6}{90}
\newlabel{refsection:6}{{\M@TitleReference {}{}}{90}{}{section*.135}{}}
\@writefile{toc}{\contentsline {section}{\numberline {3.6}Supplementary Information Chapter 3}{90}{section.3.6}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {3.7}Mathematical descriptions}{90}{section.3.7}\protected@file@percent }
\newlabel{sec:math}{{\M@TitleReference {3.7}{Mathematical descriptions}}{90}{Mathematical descriptions}{section.3.7}{}}
\@writefile{toc}{\contentsline {subsection}{Light-related terminology.}{90}{section*.136}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{Testing for linearity between bacterial density and luminescent light intensity.}{90}{section*.137}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{Rate of change of CFU count.}{91}{section*.138}\protected@file@percent }
\newlabel{eq:cluster_size}{{3.3}{92}{Rate of change of CFU count}{equation.3.7.3}{}}
\newlabel{eq:form_prob}{{3.4}{92}{Rate of change of CFU count}{equation.3.7.4}{}}
\newlabel{eq:psi_cfu}{{3.6}{92}{Rate of change of CFU count}{equation.3.7.6}{}}
\@writefile{toc}{\contentsline {subsection}{Rate of change of luminescence.}{92}{section*.139}\protected@file@percent }
\newlabel{eq:psi_I}{{3.9}{93}{Rate of change of luminescence}{equation.3.7.9}{}}
\@writefile{toc}{\contentsline {subsection}{Rate of change of volume-corrected luminescence.}{93}{section*.140}\protected@file@percent }
\newlabel{eq:I_vol}{{3.11}{93}{Rate of change of volume-corrected luminescence}{equation.3.7.11}{}}
\newlabel{eq:psi_J}{{3.12}{93}{Rate of change of volume-corrected luminescence}{equation.3.7.12}{}}
\@writefile{toc}{\contentsline {subsection}{Change of light intensity is closer to the rate of change of total cell-volume than to the rate of change of number of bacteria.}{94}{section*.141}\protected@file@percent }
\newlabel{eq:psi_V}{{3.15}{94}{Change of light intensity is closer to the rate of change of total cell-volume than to the rate of change of number of bacteria}{equation.3.7.15}{}}
\newlabel{eq:psi_V_B}{{3.16}{94}{Change of light intensity is closer to the rate of change of total cell-volume than to the rate of change of number of bacteria}{equation.3.7.16}{}}
\newlabel{eq:psi_J_ge_B}{{3.17}{94}{Change of light intensity is closer to the rate of change of total cell-volume than to the rate of change of number of bacteria}{equation.3.7.17}{}}
\newlabel{eq:theta}{{3.20}{94}{Change of light intensity is closer to the rate of change of total cell-volume than to the rate of change of number of bacteria}{equation.3.7.20}{}}
\abx@aux@cite{Coates2018}
\abx@aux@segm{6}{0}{Coates2018}
\abx@aux@cite{Novozhilov2006}
\abx@aux@segm{6}{0}{Novozhilov2006}
\abx@aux@cite{Kendall1948}
\abx@aux@segm{6}{0}{Kendall1948}
\abx@aux@cite{Feller1939}
\abx@aux@segm{6}{0}{Feller1939}
\abx@aux@cite{Coates2018}
\abx@aux@segm{6}{0}{Coates2018}
\newlabel{eq:psi_L_V}{{3.22}{95}{Change of light intensity is closer to the rate of change of total cell-volume than to the rate of change of number of bacteria}{equation.3.7.22}{}}
\newlabel{eq:I_V_B}{{3.23}{95}{Change of light intensity is closer to the rate of change of total cell-volume than to the rate of change of number of bacteria}{equation.3.7.23}{}}
\newlabel{ssec:markov}{{\M@TitleReference {3.7}{Colony formation -- birth-death Markov Model.}}{95}{Colony formation -- birth-death Markov Model}{section*.142}{}}
\@writefile{toc}{\contentsline {subsection}{Colony formation -- birth-death Markov Model.}{95}{section*.142}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{Colony formation for bacteriostatic and bactericidal drugs.}{95}{section*.143}\protected@file@percent }
\newlabel{eq:pE_cidal}{{3.30}{96}{Colony formation for bacteriostatic and bactericidal drugs}{equation.3.7.30}{}}
\@writefile{toc}{\contentsline {section}{\numberline {3.8}Filamentation Model}{96}{section.3.8}\protected@file@percent }
\newlabel{sec:model}{{\M@TitleReference {3.8}{Filamentation Model}}{96}{Filamentation Model}{section.3.8}{}}
\newlabel{eq:filamentation-ode}{{3.32}{97}{Filamentation Model}{equation.3.8.32}{}}
\@writefile{toc}{\contentsline {subsection}{Populationlevel quantities.}{98}{section*.144}\protected@file@percent }
\newlabel{eq:dbdt}{{3.38}{98}{Populationlevel quantities}{equation.3.8.38}{}}
\newlabel{eq:dVdt}{{3.39}{98}{Populationlevel quantities}{equation.3.8.39}{}}
\newlabel{eq:dvdt}{{3.40}{98}{Populationlevel quantities}{equation.3.8.40}{}}
\newlabel{eq:b_sol}{{3.42}{98}{Populationlevel quantities}{equation.3.8.42}{}}
\newlabel{eq:V_sol}{{3.43}{98}{Populationlevel quantities}{equation.3.8.43}{}}
\newlabel{eq:v_sol}{{3.44}{98}{Populationlevel quantities}{equation.3.8.44}{}}
\@writefile{toc}{\contentsline {subsection}{Parameter sensitivity.}{99}{section*.145}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{Volume correction and parameter estimation}{99}{section*.146}\protected@file@percent }
\newlabel{eq:v_model}{{3.45}{99}{Volume correction and parameter estimation}{equation.3.8.45}{}}
\newlabel{eq:alpha_constraint}{{3.46}{99}{Volume correction and parameter estimation}{equation.3.8.46}{}}
\newlabel{eq:I_model}{{3.47}{99}{Volume correction and parameter estimation}{equation.3.8.47}{}}
\newlabel{eq:F_def}{{3.48}{99}{Volume correction and parameter estimation}{equation.3.8.48}{}}
\newlabel{eq:lnI}{{3.49}{99}{Volume correction and parameter estimation}{equation.3.8.49}{}}
\newlabel{eq:I_star}{{3.50}{100}{Volume correction and parameter estimation}{equation.3.8.50}{}}
\newlabel{eq:L_mini}{{3.51}{100}{Volume correction and parameter estimation}{equation.3.8.51}{}}
\newlabel{sec:experiments}{{\M@TitleReference {3.9}{Experiments}}{100}{Experiments}{section.3.9}{}}
\@writefile{toc}{\contentsline {section}{\numberline {3.9}Experiments}{100}{section.3.9}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{SOS experiment.}{100}{section*.147}\protected@file@percent }
\abx@aux@cite{soft_code}
\abx@aux@segm{6}{0}{soft_code}
\@writefile{toc}{\contentsline {subsection}{Morphology evaluation.}{101}{section*.148}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{Antimicrobial peptide deactivation experiment.}{102}{section*.149}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{Manual pexiganan time-kill curve experiment.}{102}{section*.150}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{Supernatant experiment.}{103}{section*.151}\protected@file@percent }
\@writefile{lot}{\contentsline {table}{\numberline {3.1}{\ignorespaces  Drugs used in this study, their MICs, working concentrations, and stock solvents. In the MIC column, we report the highest concentration of the dilution series (numerator) and the maximum inhibiting dilution (denominator). Kanamycin (\SI {50}{\micro \gram \per \milli \liter }) was used as the selection marker for the \textit  {lux} operon. \relax }}{104}{table.caption.152}\protected@file@percent }
\newlabel{tab:drugs}{{\M@TitleReference {3.1}{ Drugs used in this study, their MICs, working concentrations, and stock solvents. In the MIC column, we report the highest concentration of the dilution series (numerator) and the maximum inhibiting dilution (denominator). Kanamycin (\SI {50}{\micro \gram \per \milli \liter }) was used as the selection marker for the \textit  {lux} operon. \relax }}{104}{ Drugs used in this study, their MICs, working concentrations, and stock solvents. In the MIC column, we report the highest concentration of the dilution series (numerator) and the maximum inhibiting dilution (denominator). Kanamycin (\SI {50}{\micro \gram \per \milli \liter }) was used as the selection marker for the \textit {lux} operon. \relax }{table.caption.152}{}}
\@writefile{lot}{\contentsline {table}{\numberline {3.2}{\ignorespaces  Point estimates and 95\% percentile intervals of $\mitpsi _\mathrm {CFU}$, $\mitpsi _I$, $\mitpsi _I^*$, and $\mitpsi _J$ for different treatments. Sig$_X$ indicates whether the rate of change of signal $X \in \{I, I^*, J\}$ differs significantly (*) from the distribution of $\mitpsi _\mathrm {CFU}$, or not (n.s.), based on the significance criterion defined in the Methods section. Estimates are based on data from the CFU-luminescence assays (see Methods). \relax }}{105}{table.caption.153}\protected@file@percent }
\newlabel{tab:comp_stats}{{\M@TitleReference {3.2}{ Point estimates and 95\% percentile intervals of $\mitpsi _\mathrm {CFU}$, $\mitpsi _I$, $\mitpsi _I^*$, and $\mitpsi _J$ for different treatments. Sig$_X$ indicates whether the rate of change of signal $X \in \{I, I^*, J\}$ differs significantly (*) from the distribution of $\mitpsi _\mathrm {CFU}$, or not (n.s.), based on the significance criterion defined in the Methods section. Estimates are based on data from the CFU-luminescence assays (see Methods). \relax }}{105}{ Point estimates and 95\% percentile intervals of $\psi _\mathrm {CFU}$, $\psi _I$, $\psi _I^*$, and $\psi _J$ for different treatments. Sig$_X$ indicates whether the rate of change of signal $X \in \{I, I^*, J\}$ differs significantly (*) from the distribution of $\psi _\mathrm {CFU}$, or not (n.s.), based on the significance criterion defined in the Methods section. Estimates are based on data from the CFU-luminescence assays (see Methods). \relax }{table.caption.153}{}}
\@writefile{lot}{\contentsline {table}{\numberline {3.3}{\ignorespaces  Bootstrapped 95\% confidence intervals and point estimates for the length, width, and volume of cells after 2\tmspace  +\thinmuskip {.1667em}h of treatment, estimated from microscopy images. Significance was assessed by comparing the confidence intervals of cell volumes for each antibiotic treatment to the untreated control (\texttt  {control\_2h}), as described in the Methods section of the main paper.\relax }}{106}{table.caption.154}\protected@file@percent }
\newlabel{tab:morph_post}{{\M@TitleReference {3.3}{ Bootstrapped 95\% confidence intervals and point estimates for the length, width, and volume of cells after 2\tmspace  +\thinmuskip {.1667em}h of treatment, estimated from microscopy images. Significance was assessed by comparing the confidence intervals of cell volumes for each antibiotic treatment to the untreated control (\texttt  {control\_2h}), as described in the Methods section of the main paper.\relax }}{106}{ Bootstrapped 95\% confidence intervals and point estimates for the length, width, and volume of cells after 2\,h of treatment, estimated from microscopy images. Significance was assessed by comparing the confidence intervals of cell volumes for each antibiotic treatment to the untreated control (\texttt {control\_2h}), as described in the Methods section of the main paper.\relax }{table.caption.154}{}}
\@writefile{lot}{\contentsline {table}{\numberline {3.4}{\ignorespaces  Estimated group means and $95\%$ confidence intervals from an ordinary least squares (OLS) model fitted to log-transformed CFU data, collected from the first sampled time point after diluting pexiganan-treated strains in supplemented PBS. Grouping is based on the supplement (\ce {CaCl2} or \ce {MgCl2}) and concentration (\SIrange {0}{100}{\milli M}). Confidence intervals were computed using heteroscedasticity-consistent standard errors (HC3). The compact letter display (cld) indicates groups that are not significantly different by sharing a common letter, based on mutual inclusion of their $95\%$ confidence intervals.\relax }}{106}{table.caption.155}\protected@file@percent }
\newlabel{tab:pbs_ols}{{\M@TitleReference {3.4}{ Estimated group means and $95\%$ confidence intervals from an ordinary least squares (OLS) model fitted to log-transformed CFU data, collected from the first sampled time point after diluting pexiganan-treated strains in supplemented PBS. Grouping is based on the supplement (\ce {CaCl2} or \ce {MgCl2}) and concentration (\SIrange {0}{100}{\milli M}). Confidence intervals were computed using heteroscedasticity-consistent standard errors (HC3). The compact letter display (cld) indicates groups that are not significantly different by sharing a common letter, based on mutual inclusion of their $95\%$ confidence intervals.\relax }}{106}{ Estimated group means and $95\%$ confidence intervals from an ordinary least squares (OLS) model fitted to log-transformed CFU data, collected from the first sampled time point after diluting pexiganan-treated strains in supplemented PBS. Grouping is based on the supplement (\ce {CaCl2} or \ce {MgCl2}) and concentration (\SIrange {0}{100}{\milli M}). Confidence intervals were computed using heteroscedasticity-consistent standard errors (HC3). The compact letter display (cld) indicates groups that are not significantly different by sharing a common letter, based on mutual inclusion of their $95\%$ confidence intervals.\relax }{table.caption.155}{}}
\@writefile{lot}{\contentsline {table}{\numberline {3.5}{\ignorespaces Comparison of kill rates [$h^{-1}$] between cultures treated with pexiganan (\SI {16}{\micro \gram \per \milli \liter }) for 5 minutes and cultures exposed to the supernatant collected after the kill assay. The two rates differ significantly; the confidence interval of the rate of change of CFU in the supernatant includes zero.\relax }}{107}{table.caption.156}\protected@file@percent }
\newlabel{tab:supernatant}{{\M@TitleReference {3.5}{Comparison of kill rates [$h^{-1}$] between cultures treated with pexiganan (\SI {16}{\micro \gram \per \milli \liter }) for 5 minutes and cultures exposed to the supernatant collected after the kill assay. The two rates differ significantly; the confidence interval of the rate of change of CFU in the supernatant includes zero.\relax }}{107}{Comparison of kill rates [$h^{-1}$] between cultures treated with pexiganan (\SI {16}{\micro \gram \per \milli \liter }) for 5 minutes and cultures exposed to the supernatant collected after the kill assay. The two rates differ significantly; the confidence interval of the rate of change of CFU in the supernatant includes zero.\relax }{table.caption.156}{}}
\@writefile{lot}{\contentsline {table}{\numberline {3.6}{\ignorespaces Primer sequences used for $\mitlambda $-red mediated integration of the \emph  {luxCDABE} operon into \textit  {E. coli}. Lowercase letters indicate homology regions binding to the \emph  {lux} operon on the plasmid; uppercase letters indicate chromosomal homology regions at the integration site.\relax }}{107}{table.caption.157}\protected@file@percent }
\newlabel{tab:primers}{{\M@TitleReference {3.6}{Primer sequences used for $\mitlambda $-red mediated integration of the \emph  {luxCDABE} operon into \textit  {E. coli}. Lowercase letters indicate homology regions binding to the \emph  {lux} operon on the plasmid; uppercase letters indicate chromosomal homology regions at the integration site.\relax }}{107}{Primer sequences used for $\lambda $-red mediated integration of the \emph {luxCDABE} operon into \textit {E. coli}. Lowercase letters indicate homology regions binding to the \emph {lux} operon on the plasmid; uppercase letters indicate chromosomal homology regions at the integration site.\relax }{table.caption.157}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.4}{\ignorespaces  Light intensity scales linearly with bacterial density. Serial tenfold dilutions of bacterial cultures were prepared in a 384well white microplate, and luminescence was measured immediately. Linear regression of the luminescence signal against bacterial density (CFU) yielded a conversion factor of \(m_{\mathrm {fit}} = 0.006\tmspace  +\thinmuskip {.1667em}\mathrm {rlu \cdot ml \cdot CFU}^{-1}\). The high correlation (\(R^2 = 0.987\) in log-log space) confirms a linear relationship between luminescence and bacterial density. \relax }}{107}{figure.caption.158}\protected@file@percent }
\newlabel{fig:linearity}{{\M@TitleReference {3.4}{ Light intensity scales linearly with bacterial density. Serial tenfold dilutions of bacterial cultures were prepared in a 384well white microplate, and luminescence was measured immediately. Linear regression of the luminescence signal against bacterial density (CFU) yielded a conversion factor of \(m_{\mathrm {fit}} = 0.006\tmspace  +\thinmuskip {.1667em}\mathrm {rlu \cdot ml \cdot CFU}^{-1}\). The high correlation (\(R^2 = 0.987\) in log-log space) confirms a linear relationship between luminescence and bacterial density. \relax }}{107}{ Light intensity scales linearly with bacterial density. Serial tenfold dilutions of bacterial cultures were prepared in a 384well white microplate, and luminescence was measured immediately. Linear regression of the luminescence signal against bacterial density (CFU) yielded a conversion factor of \(m_{\mathrm {fit}} = 0.006\,\mathrm {rlu \cdot ml \cdot CFU}^{-1}\). The high correlation (\(R^2 = 0.987\) in log-log space) confirms a linear relationship between luminescence and bacterial density. \relax }{figure.caption.158}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.5}{\ignorespaces Ampicillin. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. The morphology-corrected luminescence signal is shown as orange pentagons with red frames, and the corresponding rate fit indicated by a red line. `+' indicates data points below detection limit or otherwise excluded (for CFU, symbolically plotted at \SI {e4}{CFU/\milli \liter } to visualize missing data), and If a signal ends early (due to dropping below its detection limit), the corresponding data point of the other signal was cut to the same endpoint for a consitent comparison. These excluded data points are marked as `X'.\relax }}{108}{figure.caption.159}\protected@file@percent }
\newlabel{fig:ampicillin_comp_combined}{{\M@TitleReference {3.5}{Ampicillin. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. The morphology-corrected luminescence signal is shown as orange pentagons with red frames, and the corresponding rate fit indicated by a red line. `+' indicates data points below detection limit or otherwise excluded (for CFU, symbolically plotted at \SI {e4}{CFU/\milli \liter } to visualize missing data), and If a signal ends early (due to dropping below its detection limit), the corresponding data point of the other signal was cut to the same endpoint for a consitent comparison. These excluded data points are marked as `X'.\relax }}{108}{Ampicillin. \cbase . \cmorph . \cplus , and \cx .\relax }{figure.caption.159}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.6}{\ignorespaces Cefepime. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. Green-framed data points and corresponding green fit lines indicate analyses excluding early data points until the first peak.\relax }}{109}{figure.caption.160}\protected@file@percent }
\newlabel{fig:cefepime_comp}{{\M@TitleReference {3.6}{Cefepime. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. Green-framed data points and corresponding green fit lines indicate analyses excluding early data points until the first peak.\relax }}{109}{Cefepime. \cbase . \cpeak .\relax }{figure.caption.160}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.7}{\ignorespaces Ceftazidime. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. The morphology-corrected luminescence signal is shown as orange pentagons with red frames, and the corresponding rate fit indicated by a red line. \relax }}{110}{figure.caption.161}\protected@file@percent }
\newlabel{fig:ceftazidime_comp}{{\M@TitleReference {3.7}{Ceftazidime. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. The morphology-corrected luminescence signal is shown as orange pentagons with red frames, and the corresponding rate fit indicated by a red line. \relax }}{110}{Ceftazidime. \cbase . \cmorph . \relax }{figure.caption.161}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.8}{\ignorespaces Cefuroxime. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. `+' indicates data points below detection limit or otherwise excluded (for CFU, symbolically plotted at \SI {e4}{CFU/\milli \liter } to visualize missing data).\relax }}{111}{figure.caption.162}\protected@file@percent }
\newlabel{fig:cefuroxime_comp}{{\M@TitleReference {3.8}{Cefuroxime. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. `+' indicates data points below detection limit or otherwise excluded (for CFU, symbolically plotted at \SI {e4}{CFU/\milli \liter } to visualize missing data).\relax }}{111}{Cefuroxime. \cbase . \cplus .\relax }{figure.caption.162}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.9}{\ignorespaces Chloramphenicol. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals.\relax }}{112}{figure.caption.163}\protected@file@percent }
\newlabel{fig:chloramphenicol_comp}{{\M@TitleReference {3.9}{Chloramphenicol. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals.\relax }}{112}{Chloramphenicol. \cbase .\relax }{figure.caption.163}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.10}{\ignorespaces Ciprofloxacin. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. The morphology-corrected luminescence signal is shown as orange pentagons with red frames, and the corresponding rate fit indicated by a red line.\relax }}{113}{figure.caption.164}\protected@file@percent }
\newlabel{fig:ciprofloxacin_comp}{{\M@TitleReference {3.10}{Ciprofloxacin. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. The morphology-corrected luminescence signal is shown as orange pentagons with red frames, and the corresponding rate fit indicated by a red line.\relax }}{113}{Ciprofloxacin. \cbase . \cmorph .\relax }{figure.caption.164}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.11}{\ignorespaces Colistin. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. `+' indicates data points below detection limit or otherwise excluded (for CFU, symbolically plotted at \SI {e4}{CFU/\milli \liter } to visualize missing data)\relax }}{114}{figure.caption.165}\protected@file@percent }
\newlabel{fig:colistin_comp}{{\M@TitleReference {3.11}{Colistin. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. `+' indicates data points below detection limit or otherwise excluded (for CFU, symbolically plotted at \SI {e4}{CFU/\milli \liter } to visualize missing data)\relax }}{114}{Colistin. \cbase . \cplus \relax }{figure.caption.165}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.12}{\ignorespaces Doripenem. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. Green-framed data points and corresponding green fit lines indicate analyses excluding early data points until the first peak.\relax }}{115}{figure.caption.166}\protected@file@percent }
\newlabel{fig:doripenem_comp}{{\M@TitleReference {3.12}{Doripenem. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. Green-framed data points and corresponding green fit lines indicate analyses excluding early data points until the first peak.\relax }}{115}{Doripenem. \cbase . \cpeak .\relax }{figure.caption.166}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.13}{\ignorespaces Fosfomycin. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. \relax }}{115}{figure.caption.167}\protected@file@percent }
\newlabel{fig:fosfomycin_comp}{{\M@TitleReference {3.13}{Fosfomycin. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. \relax }}{115}{Fosfomycin. \cbase . \relax }{figure.caption.167}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.14}{\ignorespaces Imipenem. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. `+' indicates data points below detection limit or otherwise excluded (for CFU, symbolically plotted at \SI {e4}{CFU/\milli \liter } to visualize missing data).\relax }}{116}{figure.caption.168}\protected@file@percent }
\newlabel{fig:imipenem_comp}{{\M@TitleReference {3.14}{Imipenem. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. `+' indicates data points below detection limit or otherwise excluded (for CFU, symbolically plotted at \SI {e4}{CFU/\milli \liter } to visualize missing data).\relax }}{116}{Imipenem. \cbase . \cplus .\relax }{figure.caption.168}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.15}{\ignorespaces Mecillinam. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals.\relax }}{117}{figure.caption.169}\protected@file@percent }
\newlabel{fig:mecillinam_comp}{{\M@TitleReference {3.15}{Mecillinam. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals.\relax }}{117}{Mecillinam. \cbase .\relax }{figure.caption.169}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.16}{\ignorespaces Meropenem. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. The morphology-corrected luminescence signal is shown as orange pentagons with red frames, and the corresponding rate fit indicated by a red line. `+' indicates data points below detection limit or otherwise excluded (for CFU, symbolically plotted at \SI {e4}{CFU/\milli \liter } to visualize missing data).\relax }}{118}{figure.caption.170}\protected@file@percent }
\newlabel{fig:meropenem_comp}{{\M@TitleReference {3.16}{Meropenem. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. The morphology-corrected luminescence signal is shown as orange pentagons with red frames, and the corresponding rate fit indicated by a red line. `+' indicates data points below detection limit or otherwise excluded (for CFU, symbolically plotted at \SI {e4}{CFU/\milli \liter } to visualize missing data).\relax }}{118}{Meropenem. \cbase . \cmorph . \cplus .\relax }{figure.caption.170}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.17}{\ignorespaces Penicillin. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. `+' indicates data points below detection limit or otherwise excluded (for CFU, symbolically plotted at \SI {e4}{CFU/\milli \liter } to visualize missing data), and If a signal ends early (due to dropping below its detection limit), the corresponding data point of the other signal was cut to the same endpoint for a consitent comparison. These excluded data points are marked as `X'.\relax }}{119}{figure.caption.171}\protected@file@percent }
\newlabel{fig:penicillin_comp}{{\M@TitleReference {3.17}{Penicillin. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. `+' indicates data points below detection limit or otherwise excluded (for CFU, symbolically plotted at \SI {e4}{CFU/\milli \liter } to visualize missing data), and If a signal ends early (due to dropping below its detection limit), the corresponding data point of the other signal was cut to the same endpoint for a consitent comparison. These excluded data points are marked as `X'.\relax }}{119}{Penicillin. \cbase . \cplus , and \cx .\relax }{figure.caption.171}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.18}{\ignorespaces Piperacillin. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. \relax }}{120}{figure.caption.172}\protected@file@percent }
\newlabel{fig:piperacillin_comp}{{\M@TitleReference {3.18}{Piperacillin. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. \relax }}{120}{Piperacillin. \cbase . \relax }{figure.caption.172}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.19}{\ignorespaces Polymyxin B. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. `+' indicates data points below detection limit or otherwise excluded (for CFU, symbolically plotted at \SI {e4}{CFU/\milli \liter } to visualize missing data).\relax }}{121}{figure.caption.173}\protected@file@percent }
\newlabel{fig:polymyxinB_comp}{{\M@TitleReference {3.19}{Polymyxin B. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. `+' indicates data points below detection limit or otherwise excluded (for CFU, symbolically plotted at \SI {e4}{CFU/\milli \liter } to visualize missing data).\relax }}{121}{Polymyxin B. \cbase . \cplus .\relax }{figure.caption.173}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.20}{\ignorespaces Rifampicin (\SI {25}{\micro \gram /\milli \liter }). The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals.\relax }}{122}{figure.caption.174}\protected@file@percent }
\newlabel{fig:rifampicin_comp}{{\M@TitleReference {3.20}{Rifampicin (\SI {25}{\micro \gram /\milli \liter }). The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals.\relax }}{122}{Rifampicin (\SI {25}{\micro \gram /\milli \liter }). \cbase .\relax }{figure.caption.174}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.21}{\ignorespaces Tetracycline. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals.\relax }}{122}{figure.caption.175}\protected@file@percent }
\newlabel{fig:tetracycline_comp}{{\M@TitleReference {3.21}{Tetracycline. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals.\relax }}{122}{Tetracycline. \cbase .\relax }{figure.caption.175}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.22}{\ignorespaces Trimethoprim. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. The morphology-corrected luminescence signal is shown as orange pentagons with red frames, and the corresponding rate fit indicated by a red line.\relax }}{123}{figure.caption.176}\protected@file@percent }
\newlabel{fig:trimethoprim_comp}{{\M@TitleReference {3.22}{Trimethoprim. The CFU signal is shown as blue diamonds and the light intensity as orange triangles for data points above their respective detection limits (\SI {e4}{CFU/\milli \liter } for CFU and 20~rlu for luminescence). Lines represent log-linear fits to the corresponding signals. The morphology-corrected luminescence signal is shown as orange pentagons with red frames, and the corresponding rate fit indicated by a red line.\relax }}{123}{Trimethoprim. \cbase . \cmorph .\relax }{figure.caption.176}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.23}{\ignorespaces Comparison of the CFU and luminescence signals from the pexiganan kill curve experiment using the liquid handling platform. The first data points at $t_0$ represent the pretreatment CFU and light intensity values.\relax }}{124}{figure.caption.177}\protected@file@percent }
\newlabel{fig:pex_robo}{{\M@TitleReference {3.23}{Comparison of the CFU and luminescence signals from the pexiganan kill curve experiment using the liquid handling platform. The first data points at $t_0$ represent the pretreatment CFU and light intensity values.\relax }}{124}{Comparison of the CFU and luminescence signals from the pexiganan kill curve experiment using the liquid handling platform. The first data points at $t_0$ represent the pretreatment CFU and light intensity values.\relax }{figure.caption.177}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.24}{\ignorespaces Panel plot showing the effects of UV treatment on bacterial density (approximated by OD) and light intensity (I) over time by comparing treated (UV) and untreated (ctrl) cultures. (a) Optical density (OD), (b) light intensity, (c) OD-specific light intensity $\mitomega = I(t)/\mathrm {OD}(t)$, and (d) the difference in OD-specific light intensity between UV-treated and control.\relax }}{125}{figure.caption.178}\protected@file@percent }
\newlabel{fig:SOS}{{\M@TitleReference {3.24}{Panel plot showing the effects of UV treatment on bacterial density (approximated by OD) and light intensity (I) over time by comparing treated (UV) and untreated (ctrl) cultures. (a) Optical density (OD), (b) light intensity, (c) OD-specific light intensity $\mitomega = I(t)/\mathrm {OD}(t)$, and (d) the difference in OD-specific light intensity between UV-treated and control.\relax }}{125}{Panel plot showing the effects of UV treatment on bacterial density (approximated by OD) and light intensity (I) over time by comparing treated (UV) and untreated (ctrl) cultures. (a) Optical density (OD), (b) light intensity, (c) OD-specific light intensity $\omega = I(t)/\mathrm {OD}(t)$, and (d) the difference in OD-specific light intensity between UV-treated and control.\relax }{figure.caption.178}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.25}{\ignorespaces  Microscopy images of control (before treatment) samples. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{125}{figure.caption.179}\protected@file@percent }
\newlabel{fig:micro_ctrl0}{{\M@TitleReference {3.25}{ Microscopy images of control (before treatment) samples. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{125}{ Microscopy images of control (before treatment) samples. Each image represents a different replicate. \clegend \relax }{figure.caption.179}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.26}{\ignorespaces  Microscopy images of control (after 2 hours) samples. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{126}{figure.caption.180}\protected@file@percent }
\newlabel{fig:micro_ctrl2}{{\M@TitleReference {3.26}{ Microscopy images of control (after 2 hours) samples. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{126}{ Microscopy images of control (after 2 hours) samples. Each image represents a different replicate. \clegend \relax }{figure.caption.180}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.27}{\ignorespaces  Microscopy images of cells treated with ampicillin. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{126}{figure.caption.181}\protected@file@percent }
\newlabel{fig:micro_amp}{{\M@TitleReference {3.27}{ Microscopy images of cells treated with ampicillin. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{126}{ Microscopy images of cells treated with ampicillin. Each image represents a different replicate. \clegend \relax }{figure.caption.181}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.28}{\ignorespaces  Microscopy images of cells treated with amoxicillin. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{127}{figure.caption.182}\protected@file@percent }
\newlabel{fig:micro_amx}{{\M@TitleReference {3.28}{ Microscopy images of cells treated with amoxicillin. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{127}{ Microscopy images of cells treated with amoxicillin. Each image represents a different replicate. \clegend \relax }{figure.caption.182}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.29}{\ignorespaces  Microscopy images of cells treated with ceftazidime. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{127}{figure.caption.183}\protected@file@percent }
\newlabel{fig:micro_caz}{{\M@TitleReference {3.29}{ Microscopy images of cells treated with ceftazidime. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{127}{ Microscopy images of cells treated with ceftazidime. Each image represents a different replicate. \clegend \relax }{figure.caption.183}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.30}{\ignorespaces  Microscopy images of cells treated with ciprofloxacin. Each image represents a different replicate. The white gaps can indicate the start of cell division (cells are not fixed). We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{128}{figure.caption.184}\protected@file@percent }
\newlabel{fig:micro_cip}{{\M@TitleReference {3.30}{ Microscopy images of cells treated with ciprofloxacin. Each image represents a different replicate. The white gaps can indicate the start of cell division (cells are not fixed). We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{128}{ Microscopy images of cells treated with ciprofloxacin. Each image represents a different replicate. The white gaps can indicate the start of cell division (cells are not fixed). \clegend \relax }{figure.caption.184}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.31}{\ignorespaces  Microscopy images of cells treated with colistin. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{128}{figure.caption.185}\protected@file@percent }
\newlabel{fig:micro_col}{{\M@TitleReference {3.31}{ Microscopy images of cells treated with colistin. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{128}{ Microscopy images of cells treated with colistin. Each image represents a different replicate. \clegend \relax }{figure.caption.185}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.32}{\ignorespaces  Microscopy images of cells treated with fosfomycin. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{129}{figure.caption.186}\protected@file@percent }
\newlabel{fig:micro_fos}{{\M@TitleReference {3.32}{ Microscopy images of cells treated with fosfomycin. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{129}{ Microscopy images of cells treated with fosfomycin. Each image represents a different replicate. \clegend \relax }{figure.caption.186}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.33}{\ignorespaces  Microscopy images of cells treated with meropenem. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{129}{figure.caption.187}\protected@file@percent }
\newlabel{fig:micro_mero}{{\M@TitleReference {3.33}{ Microscopy images of cells treated with meropenem. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{129}{ Microscopy images of cells treated with meropenem. Each image represents a different replicate. \clegend \relax }{figure.caption.187}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.34}{\ignorespaces  Microscopy images of cells treated with pexiganan. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{130}{figure.caption.188}\protected@file@percent }
\newlabel{fig:micro_pex}{{\M@TitleReference {3.34}{ Microscopy images of cells treated with pexiganan. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{130}{ Microscopy images of cells treated with pexiganan. Each image represents a different replicate. \clegend \relax }{figure.caption.188}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.35}{\ignorespaces  Microscopy images of cells treated with rifampicin. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{130}{figure.caption.189}\protected@file@percent }
\newlabel{fig:micro_rif}{{\M@TitleReference {3.35}{ Microscopy images of cells treated with rifampicin. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{130}{ Microscopy images of cells treated with rifampicin. Each image represents a different replicate. \clegend \relax }{figure.caption.189}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.36}{\ignorespaces  Microscopy images of cells treated with tetracycline. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{131}{figure.caption.190}\protected@file@percent }
\newlabel{fig:micro_tet}{{\M@TitleReference {3.36}{ Microscopy images of cells treated with tetracycline. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{131}{ Microscopy images of cells treated with tetracycline. Each image represents a different replicate. \clegend \relax }{figure.caption.190}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.37}{\ignorespaces  Microscopy images of cells treated with trimethoprim. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{131}{figure.caption.191}\protected@file@percent }
\newlabel{fig:micro_tri}{{\M@TitleReference {3.37}{ Microscopy images of cells treated with trimethoprim. Each image represents a different replicate. We plotted the green channel of the recorded images in greyscale. The red channel, capturing propidium iodide activity, is overlaid in red. Bacterial shapes detected by the algorithm are outlined in cyan.\relax }}{131}{ Microscopy images of cells treated with trimethoprim. Each image represents a different replicate. \clegend \relax }{figure.caption.191}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.38}{\ignorespaces  Pooled density distributions (95\% prediction intervals) of cell widths (red) and lengths (blue), obtained from microscopy images (a) before and (b) after 2\tmspace  +\thinmuskip {.1667em}h of antibiotic treatment. Boxes indicate the interquartile range (Q1Q3), and the mean is marked by ($\mid $). $\ddagger $ Poor fit quality for meropenem-treated cells, which adopt a lemon-like shape (\autoref  {fig:micro_mero}), due to our algorithm assuming cylindrical geometry. \relax }}{132}{figure.caption.192}\protected@file@percent }
\newlabel{fig:filamentation_summary}{{\M@TitleReference {3.38}{ Pooled density distributions (95\% prediction intervals) of cell widths (red) and lengths (blue), obtained from microscopy images (a) before and (b) after 2\tmspace  +\thinmuskip {.1667em}h of antibiotic treatment. Boxes indicate the interquartile range (Q1Q3), and the mean is marked by ($\mid $). $\ddagger $ Poor fit quality for meropenem-treated cells, which adopt a lemon-like shape (\autoref  {fig:micro_mero}), due to our algorithm assuming cylindrical geometry. \relax }}{132}{ Pooled density distributions (95\% prediction intervals) of cell widths (red) and lengths (blue), obtained from microscopy images (a) before and (b) after 2\,h of antibiotic treatment. Boxes indicate the interquartile range (Q1Q3), and the mean is marked by ($\mid $). $\ddagger $ Poor fit quality for meropenem-treated cells, which adopt a lemon-like shape (\autoref {fig:micro_mero}), due to our algorithm assuming cylindrical geometry. \relax }{figure.caption.192}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.39}{\ignorespaces  Illustrative simulations using the filamentation model relating (ad) bacterial population size (blue) and light intensity (orange) under different combinations of treatment-induced changes in division rate ($\mitDelta \mitlambda $) and death rate ($\mitdelta $). Panel (e) shows the distributions of converged cell volumes for $\mitlambda = 0.3$ and $\mitlambda = 1.5$. Panel (f) shows the shift of mean cell volumes over time for $\mitDelta \mitlambda = -1.2$ and $\mitDelta \mitlambda = 0$. For all simulations, we used $\mitlambda _0 = 1.5$, $\mitgamma = 150$, $\mitphi = 0.015$, and $\mitepsilon = 0.04$. As shown in panel (b), treatment-induced filamentation can lead to a temporary discrepancy between luminescence- and CFU-based rates. \relax }}{133}{figure.caption.193}\protected@file@percent }
\newlabel{fig:filamentation_model}{{\M@TitleReference {3.39}{ Illustrative simulations using the filamentation model relating (ad) bacterial population size (blue) and light intensity (orange) under different combinations of treatment-induced changes in division rate ($\mitDelta \mitlambda $) and death rate ($\mitdelta $). Panel (e) shows the distributions of converged cell volumes for $\mitlambda = 0.3$ and $\mitlambda = 1.5$. Panel (f) shows the shift of mean cell volumes over time for $\mitDelta \mitlambda = -1.2$ and $\mitDelta \mitlambda = 0$. For all simulations, we used $\mitlambda _0 = 1.5$, $\mitgamma = 150$, $\mitphi = 0.015$, and $\mitepsilon = 0.04$. As shown in panel (b), treatment-induced filamentation can lead to a temporary discrepancy between luminescence- and CFU-based rates. \relax }}{133}{ Illustrative simulations using the filamentation model relating (ad) bacterial population size (blue) and light intensity (orange) under different combinations of treatment-induced changes in division rate ($\Delta \lambda $) and death rate ($\delta $). Panel (e) shows the distributions of converged cell volumes for $\lambda = 0.3$ and $\lambda = 1.5$. Panel (f) shows the shift of mean cell volumes over time for $\Delta \lambda = -1.2$ and $\Delta \lambda = 0$. For all simulations, we used $\lambda _0 = 1.5$, $\gamma = 150$, $\phi = 0.015$, and $\epsilon = 0.04$. As shown in panel (b), treatment-induced filamentation can lead to a temporary discrepancy between luminescence- and CFU-based rates. \relax }{figure.caption.193}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.40}{\ignorespaces Example of the probability of colony formation $p_C = 1-p_E$ (see \autoref  {sec:math}) for a single plated bacterium. Blue shows $p_C$ for a purely bactericidal drug ($\mitlambda _T = 0$) and red for a purely bacteriostatic drug ($\mitdelta _T = 0$), plotted over the treatment effect $\mittau = \mitdelta _T + \mitlambda _T$. In this illustrative example we use $\mitlambda _0 = 1.35 h^{-1}$ and $\mitdelta _0 = 0.1 h^{-1}$.\relax }}{134}{figure.caption.194}\protected@file@percent }
\newlabel{fig:colony_formation}{{\M@TitleReference {3.40}{Example of the probability of colony formation $p_C = 1-p_E$ (see \autoref  {sec:math}) for a single plated bacterium. Blue shows $p_C$ for a purely bactericidal drug ($\mitlambda _T = 0$) and red for a purely bacteriostatic drug ($\mitdelta _T = 0$), plotted over the treatment effect $\mittau = \mitdelta _T + \mitlambda _T$. In this illustrative example we use $\mitlambda _0 = 1.35 h^{-1}$ and $\mitdelta _0 = 0.1 h^{-1}$.\relax }}{134}{Example of the probability of colony formation $p_C = 1-p_E$ (see \autoref {sec:math}) for a single plated bacterium. Blue shows $p_C$ for a purely bactericidal drug ($\lambda _T = 0$) and red for a purely bacteriostatic drug ($\delta _T = 0$), plotted over the treatment effect $\tau = \delta _T + \lambda _T$. In this illustrative example we use $\lambda _0 = 1.35 h^{-1}$ and $\delta _0 = 0.1 h^{-1}$.\relax }{figure.caption.194}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.41}{\ignorespaces  CFU measured over time in supplemented dilution media. Bacterial cultures treated for 1\tmspace  +\thinmuskip {.1667em}min with \SI {16}{\mitmu g \per ml} pexiganan were diluted (1:100) in PBS supplemented with varying concentrations of (a) \ce {CaCl2} and (b) \ce {MgCl2}. Diluted samples were repeatedly plated over time to test whether supplementation prevents further bacterial killing. \relax }}{135}{figure.caption.195}\protected@file@percent }
\newlabel{fig:PBS_suppl}{{\M@TitleReference {3.41}{ CFU measured over time in supplemented dilution media. Bacterial cultures treated for 1\tmspace  +\thinmuskip {.1667em}min with \SI {16}{\mitmu g \per ml} pexiganan were diluted (1:100) in PBS supplemented with varying concentrations of (a) \ce {CaCl2} and (b) \ce {MgCl2}. Diluted samples were repeatedly plated over time to test whether supplementation prevents further bacterial killing. \relax }}{135}{ CFU measured over time in supplemented dilution media. Bacterial cultures treated for 1\,min with \SI {16}{\mu g \per ml} pexiganan were diluted (1:100) in PBS supplemented with varying concentrations of (a) \ce {CaCl2} and (b) \ce {MgCl2}. Diluted samples were repeatedly plated over time to test whether supplementation prevents further bacterial killing. \relax }{figure.caption.195}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.42}{\ignorespaces  CFU time-kill curves for pexiganan, performed manually, comparing dilution in (a) unsupplemented PBS and (b) PBS supplemented with \SI {100}{\milli M} MgCl$_2$. Timepoints correspond to: $t_0 \approx 0\tmspace  +\thinmuskip {.1667em}\mathrm {s}$, $t_1 \approx 20\tmspace  +\thinmuskip {.1667em}\mathrm {s}$, $t_2 \approx 2\tmspace  +\thinmuskip {.1667em}\mathrm {min}$, $t_3 \approx 3\tmspace  +\thinmuskip {.1667em}\mathrm {min}\tmspace  +\thinmuskip {.1667em}20\tmspace  +\thinmuskip {.1667em}\mathrm {s}$, and $t_4 \approx 5\tmspace  +\thinmuskip {.1667em}\mathrm {min}$. The black boxplot ($t_0$) indicates the pre-treatment bacterial density. \relax }}{136}{figure.caption.196}\protected@file@percent }
\newlabel{fig:pexi_hand}{{\M@TitleReference {3.42}{ CFU time-kill curves for pexiganan, performed manually, comparing dilution in (a) unsupplemented PBS and (b) PBS supplemented with \SI {100}{\milli M} MgCl$_2$. Timepoints correspond to: $t_0 \approx 0\tmspace  +\thinmuskip {.1667em}\mathrm {s}$, $t_1 \approx 20\tmspace  +\thinmuskip {.1667em}\mathrm {s}$, $t_2 \approx 2\tmspace  +\thinmuskip {.1667em}\mathrm {min}$, $t_3 \approx 3\tmspace  +\thinmuskip {.1667em}\mathrm {min}\tmspace  +\thinmuskip {.1667em}20\tmspace  +\thinmuskip {.1667em}\mathrm {s}$, and $t_4 \approx 5\tmspace  +\thinmuskip {.1667em}\mathrm {min}$. The black boxplot ($t_0$) indicates the pre-treatment bacterial density. \relax }}{136}{ CFU time-kill curves for pexiganan, performed manually, comparing dilution in (a) unsupplemented PBS and (b) PBS supplemented with \SI {100}{\milli M} MgCl$_2$. Timepoints correspond to: $t_0 \approx 0\,\mathrm {s}$, $t_1 \approx 20\,\mathrm {s}$, $t_2 \approx 2\,\mathrm {min}$, $t_3 \approx 3\,\mathrm {min}\,20\,\mathrm {s}$, and $t_4 \approx 5\,\mathrm {min}$. The black boxplot ($t_0$) indicates the pre-treatment bacterial density. \relax }{figure.caption.196}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3.43}{\ignorespaces  Experiment AMP kill curve vs supernatant kill curve. Here we show the original AMP-Killcurve in blue and the change of CFU over time in the supernatant. The error bars show the min/max interval of the three replicates. \autoref  {tab:supernatant} lists the confidence interval and mean for the bootstrapped rates. According to the significance criterion (defined in methods) these two rates are significantly different. The confidence interval of the rate of change of CFU in the supernatant includes zero.\relax }}{137}{figure.caption.197}\protected@file@percent }
\newlabel{fig:supernatant}{{\M@TitleReference {3.43}{ Experiment AMP kill curve vs supernatant kill curve. Here we show the original AMP-Killcurve in blue and the change of CFU over time in the supernatant. The error bars show the min/max interval of the three replicates. \autoref  {tab:supernatant} lists the confidence interval and mean for the bootstrapped rates. According to the significance criterion (defined in methods) these two rates are significantly different. The confidence interval of the rate of change of CFU in the supernatant includes zero.\relax }}{137}{ Experiment AMP kill curve vs supernatant kill curve. Here we show the original AMP-Killcurve in blue and the change of CFU over time in the supernatant. The error bars show the min/max interval of the three replicates. \autoref {tab:supernatant} lists the confidence interval and mean for the bootstrapped rates. According to the significance criterion (defined in methods) these two rates are significantly different. The confidence interval of the rate of change of CFU in the supernatant includes zero.\relax }{figure.caption.197}{}}
\abx@aux@refsection{7}{138}
\newlabel{refsection:7}{{\M@TitleReference {}{}}{138}{}{section*.198}{}}
\abx@aux@cite{Naghavi2024}
\abx@aux@segm{7}{0}{Naghavi2024}
\abx@aux@cite{Witzany2020}
\abx@aux@segm{7}{0}{Witzany2020}
\abx@aux@cite{Gulick1997}
\abx@aux@segm{7}{0}{Gulick1997}
\abx@aux@cite{Goldberg2012}
\abx@aux@segm{7}{0}{Goldberg2012}
\abx@aux@cite{Bonhoeffer1997}
\abx@aux@segm{7}{0}{Bonhoeffer1997}
\abx@aux@cite{Tepekule2017}
\abx@aux@segm{7}{0}{Tepekule2017}
\abx@aux@cite{Uecker2021}
\abx@aux@segm{7}{0}{Uecker2021}
\abx@aux@cite{Angst2021}
\abx@aux@segm{7}{0}{Angst2021}
\abx@aux@cite{Muetter2024}
\abx@aux@segm{7}{0}{Muetter2024}
\abx@aux@cite{Siedentop2024}
\abx@aux@segm{7}{0}{Siedentop2024}
\@writefile{lof}{\addvspace {10pt}}
\@writefile{lot}{\addvspace {10pt}}
\@writefile{toc}{\contentsline {chapter}{\chapternumberline {4}Antimicrobial Combination Effects at Subinhibitory Doses do not Reliably Predict Effects at Inhibitory Concentrations}{139}{chapter.4}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {4.1}Introduction}{139}{section.4.1}\protected@file@percent }
\abx@aux@cite{Siedentop2024}
\abx@aux@segm{7}{0}{Siedentop2024}
\abx@aux@cite{Foucquier2015}
\abx@aux@segm{7}{0}{Foucquier2015}
\abx@aux@cite{Duarte2022}
\abx@aux@segm{7}{0}{Duarte2022}
\abx@aux@cite{Bliss1939}
\abx@aux@segm{7}{0}{Bliss1939}
\abx@aux@cite{Loewe1926}
\abx@aux@segm{7}{0}{Loewe1926}
\abx@aux@cite{Bliss1939}
\abx@aux@segm{7}{0}{Bliss1939}
\abx@aux@cite{Baeder2016}
\abx@aux@segm{7}{0}{Baeder2016}
\abx@aux@cite{Frei1913}
\abx@aux@segm{7}{0}{Frei1913}
\abx@aux@cite{Loewe1926}
\abx@aux@segm{7}{0}{Loewe1926}
\abx@aux@cite{Loewe1926}
\abx@aux@segm{7}{0}{Loewe1926}
\abx@aux@cite{Regoes2004}
\abx@aux@segm{7}{0}{Regoes2004}
\abx@aux@cite{Yeh2006}
\abx@aux@segm{7}{0}{Yeh2006}
\abx@aux@cite{OShaughnessy2006}
\abx@aux@segm{7}{0}{OShaughnessy2006}
\abx@aux@cite{Chevereau2015}
\abx@aux@segm{7}{0}{Chevereau2015}
\abx@aux@cite{Russ2018}
\abx@aux@segm{7}{0}{Russ2018}
\abx@aux@cite{Katzir2019}
\abx@aux@segm{7}{0}{Katzir2019}
\abx@aux@cite{Kavcic2020}
\abx@aux@segm{7}{0}{Kavcic2020}
\abx@aux@cite{Rezzoagli2020}
\abx@aux@segm{7}{0}{Rezzoagli2020}
\abx@aux@cite{Sanchez-Hevia2025}
\abx@aux@segm{7}{0}{Sanchez-Hevia2025}
\abx@aux@cite{huntelman2023}
\abx@aux@segm{7}{0}{huntelman2023}
\abx@aux@cite{Yang2017}
\abx@aux@segm{7}{0}{Yang2017}
\abx@aux@cite{Ruden2019}
\abx@aux@segm{7}{0}{Ruden2019}
\abx@aux@cite{Liu2022}
\abx@aux@segm{7}{0}{Liu2022}
\abx@aux@cite{Ocampo2014}
\abx@aux@segm{7}{0}{Ocampo2014}
\abx@aux@cite{Rao2017}
\abx@aux@segm{7}{0}{Rao2017}
\abx@aux@cite{Yu2016}
\abx@aux@segm{7}{0}{Yu2016}
\abx@aux@cite{Caballero2018}
\abx@aux@segm{7}{0}{Caballero2018}
\abx@aux@cite{Chen2020}
\abx@aux@segm{7}{0}{Chen2020}
\abx@aux@cite{Bognar2024}
\abx@aux@segm{7}{0}{Bognar2024}
\abx@aux@cite{Yu2018}
\abx@aux@segm{7}{0}{Yu2018}
\newlabel{eq:loewe_core}{{4.2}{140}{Introduction}{equation.4.1.2}{}}
\abx@aux@cite{Chou1984}
\abx@aux@segm{7}{0}{Chou1984}
\abx@aux@cite{OShaughnessy2006}
\abx@aux@segm{7}{0}{OShaughnessy2006}
\abx@aux@cite{Meletiadis2007}
\abx@aux@segm{7}{0}{Meletiadis2007}
\abx@aux@cite{Rezzoagli2020}
\abx@aux@segm{7}{0}{Rezzoagli2020}
\abx@aux@cite{Kavcic2021}
\abx@aux@segm{7}{0}{Kavcic2021}
\abx@aux@cite{Meletiadis2007}
\abx@aux@segm{7}{0}{Meletiadis2007}
\@writefile{toc}{\contentsline {section}{\numberline {4.2}Results}{141}{section.4.2}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {4.3}Discussion}{141}{section.4.3}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {4.4}Methods}{141}{section.4.4}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {4.5}Data, Materials, and Software Availability}{141}{section.4.5}\protected@file@percent }
\abx@aux@refsection{8}{144}
\newlabel{refsection:8}{{\M@TitleReference {}{}}{144}{}{section*.200}{}}
\@writefile{toc}{\contentsline {section}{\numberline {4.6}Supplementary Information Chapter 4}{144}{section.4.6}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {4.7}SI TEXT}{145}{section.4.7}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{Time weighted net growth rates}{145}{section*.201}\protected@file@percent }
\newlabel{ssec:netgrowth}{{\M@TitleReference {4.7}{Time weighted net growth rates}}{145}{Time weighted net growth rates}{section*.201}{}}
\newlabel{eq:psi_weighted}{{4.3}{145}{Time weighted net growth rates}{equation.4.7.3}{}}
\newlabel{eq:norm}{{4.4}{145}{Time weighted net growth rates}{equation.4.7.4}{}}
\newlabel{eq:Ydef}{{4.5}{145}{Time weighted net growth rates}{equation.4.7.5}{}}
\newlabel{eq:intY}{{4.6}{145}{Time weighted net growth rates}{equation.4.7.6}{}}
\newlabel{eq:psi_eff}{{4.7}{145}{Time weighted net growth rates}{equation.4.7.7}{}}
\newlabel{eq:intYdiff}{{4.8}{145}{Time weighted net growth rates}{equation.4.7.8}{}}
\newlabel{eq:tau_eff}{{4.9}{145}{Time weighted net growth rates}{equation.4.7.9}{}}
\zref@newlabel{mdf@pagelabel-1}{\default{4.7}\page{145}\abspage{155}\mdf@pagevalue{145}}
\zref@newlabel{mdf@pagelabel-2}{\default{4.7}\page{146}\abspage{156}\mdf@pagevalue{146}}
\@writefile{toc}{\contentsline {subsection}{Quantifying Light Noise.}{147}{section*.202}\protected@file@percent }
\newlabel{ssec:lightnoise}{{\M@TitleReference {4.7}{Quantifying Light Noise.}}{147}{Quantifying Light Noise}{section*.202}{}}
\newlabel{eq:noise_corr}{{4.10}{147}{Quantifying Light Noise}{equation.4.7.10}{}}
\@writefile{toc}{\contentsline {subsection}{Drug conditions and response functions}{147}{section*.203}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Single-drug pharmacodynamic curves.}{147}{section*.204}\protected@file@percent }
\newlabel{eq:single_drug_pd_si}{{4.11}{147}{Single-drug pharmacodynamic curves}{equation.4.7.11}{}}
\@writefile{toc}{\contentsline {paragraph}{Closed-form inversion.}{147}{section*.205}\protected@file@percent }
\newlabel{eq:psi_inverse_closed_form}{{4.12}{147}{Closed-form inversion}{equation.4.7.12}{}}
\@writefile{toc}{\contentsline {paragraph}{Cartesian conditions.}{147}{section*.206}\protected@file@percent }
\abx@aux@cite{Bliss1939}
\abx@aux@segm{8}{0}{Bliss1939}
\@writefile{toc}{\contentsline {paragraph}{Polar pharmacodynamic curves.}{148}{section*.207}\protected@file@percent }
\newlabel{eq:polar_pd}{{4.13}{148}{Polar pharmacodynamic curves}{equation.4.7.13}{}}
\@writefile{toc}{\contentsline {subsection}{Bliss independence}{148}{section*.208}\protected@file@percent }
\newlabel{ssec:bliss}{{\M@TitleReference {4.7}{Bliss independence}}{148}{Bliss independence}{section*.208}{}}
\newlabel{eq:bliss_prob}{{4.14}{148}{Bliss independence}{equation.4.7.14}{}}
\@writefile{toc}{\contentsline {paragraph}{Time--varying hazards.}{148}{section*.209}\protected@file@percent }
\newlabel{eq:hazard_additivity}{{4.15}{148}{Time--varying hazards}{equation.4.7.15}{}}
\newlabel{eq:Y_additivity}{{4.16}{148}{Time--varying hazards}{equation.4.7.16}{}}
\newlabel{eq:tau_eff_bliss}{{4.17}{148}{Time--varying hazards}{equation.4.7.17}{}}
\@writefile{toc}{\contentsline {paragraph}{Bliss-based interaction index \(\mitmu \).}{148}{section*.210}\protected@file@percent }
\newlabel{eq:mu}{{4.18}{148}{Bliss-based interaction index \(\mu \)}{equation.4.7.18}{}}
\zref@newlabel{mdf@pagelabel-3}{\default{4.7}\page{149}\abspage{159}\mdf@pagevalue{149}}
\@writefile{toc}{\contentsline {subsection}{Loewe additivity}{149}{section*.211}\protected@file@percent }
\newlabel{ssec:loewe}{{\M@TitleReference {4.7}{Loewe additivity}}{149}{Loewe additivity}{section*.211}{}}
\newlabel{eq:loewe_core}{{4.19}{149}{Loewe additivity}{equation.4.7.19}{}}
\@writefile{toc}{\contentsline {paragraph}{Loewe interaction index (\(\mitnu \)).}{149}{section*.212}\protected@file@percent }
\newlabel{eq:fici}{{4.20}{149}{Loewe interaction index (\(\nu \))}{equation.4.7.20}{}}
\newlabel{eq:loewe_domain}{{4.21}{150}{Loewe interaction index (\(\nu \))}{equation.4.7.21}{}}
\zref@newlabel{mdf@pagelabel-4}{\default{4.7}\page{150}\abspage{160}\mdf@pagevalue{150}}
\@writefile{toc}{\contentsline {subsection}{Peptide--antibiotic interaction model}{151}{section*.213}\protected@file@percent }
\newlabel{ssec:toy_model}{{\M@TitleReference {4.7}{Peptide--antibiotic interaction model}}{151}{Peptide--antibiotic interaction model}{section*.213}{}}
\newlabel{eq:combined_pep}{{4.22}{151}{Peptide--antibiotic interaction model}{equation.4.7.22}{}}
\newlabel{eq:toy_model}{{4.23}{151}{Peptide--antibiotic interaction model}{equation.4.7.23}{}}
\@writefile{toc}{\contentsline {subsection}{Condition-wise interaction inference on the checkerboard}{151}{section*.214}\protected@file@percent }
\newlabel{ssec:bootstrap_interactions}{{\M@TitleReference {4.7}{Condition-wise interaction inference on the checkerboard}}{151}{Condition-wise interaction inference on the checkerboard}{section*.214}{}}
\@writefile{toc}{\contentsline {paragraph}{Regime-wise aggregation across checkerboard conditions.}{152}{section*.215}\protected@file@percent }
\newlabel{eq:weights}{{4.24}{152}{Regime-wise aggregation across checkerboard conditions}{equation.4.7.24}{}}
\abx@aux@cite{Pedregosa2011}
\abx@aux@segm{8}{0}{Pedregosa2011}
\@writefile{toc}{\contentsline {subsection}{Continuous interaction surfaces and geometric exploration}{153}{section*.216}\protected@file@percent }
\newlabel{ssec:surface}{{\M@TitleReference {4.7}{Continuous interaction surfaces and geometric exploration}}{153}{Continuous interaction surfaces and geometric exploration}{section*.216}{}}
\@writefile{toc}{\contentsline {paragraph}{Density-based restriction of the surface domain.}{153}{section*.217}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Bootstrap datasets and coordinate transform.}{153}{section*.218}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Monotone surface construction.}{153}{section*.219}\protected@file@percent }
\@writefile{toc}{\contentsline {paragraph}{Bliss and Loewe interaction indices on the surface.}{153}{section*.220}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{Single-drug inoculum effect analysis}{154}{section*.221}\protected@file@percent }
\newlabel{ssec:inoculum}{{\M@TitleReference {4.7}{Single-drug inoculum effect analysis}}{154}{Single-drug inoculum effect analysis}{section*.221}{}}
\@writefile{toc}{\contentsline {section}{\numberline {4.8}SI tables}{156}{section.4.8}\protected@file@percent }
\@writefile{lot}{\contentsline {table}{\numberline {4.1}{\ignorespaces Fitted single-drug pharmacodynamic (PD) curve parameters for \autoref  {eq:single_drug_pd_si}. For each antibiotic, we report the point estimates of $\mitpsi _0$, $\mitpsi _{\qopname  \relax m{min}}$, $\mitkappa $, and $z_{\mathrm {MIC}}$, together with the corresponding lower (L) and upper (U) uncertainty bounds (95\% intervals).\relax }}{156}{table.caption.222}\protected@file@percent }
\newlabel{tab:pd_curve_parameter}{{\M@TitleReference {4.1}{Fitted single-drug pharmacodynamic (PD) curve parameters for \autoref  {eq:single_drug_pd_si}. For each antibiotic, we report the point estimates of $\mitpsi _0$, $\mitpsi _{\qopname  \relax m{min}}$, $\mitkappa $, and $z_{\mathrm {MIC}}$, together with the corresponding lower (L) and upper (U) uncertainty bounds (95\% intervals).\relax }}{156}{Fitted single-drug pharmacodynamic (PD) curve parameters for \autoref {eq:single_drug_pd_si}. For each antibiotic, we report the point estimates of $\psi _0$, $\psi _{\min }$, $\kappa $, and $z_{\mathrm {MIC}}$, together with the corresponding lower (L) and upper (U) uncertainty bounds (95\% intervals).\relax }{table.caption.222}{}}
\@writefile{lot}{\contentsline {table}{\numberline {4.2}{\ignorespaces This table summarises interaction classifications (N: neutral, S: synergistic, A: antagonistic) for each drug combination based on Loewe additivity ($\mitmu $) and Bliss independence ($\mitnu $), evaluated separately for sub-inhibitory and inhibitory concentration regimes based on bootstrap confidence intervals.\relax }}{156}{table.caption.223}\protected@file@percent }
\newlabel{tab:intearction_summary}{{\M@TitleReference {4.2}{This table summarises interaction classifications (N: neutral, S: synergistic, A: antagonistic) for each drug combination based on Loewe additivity ($\mitmu $) and Bliss independence ($\mitnu $), evaluated separately for sub-inhibitory and inhibitory concentration regimes based on bootstrap confidence intervals.\relax }}{156}{This table summarises interaction classifications (N: neutral, S: synergistic, A: antagonistic) for each drug combination based on Loewe additivity ($\mu $) and Bliss independence ($\nu $), evaluated separately for sub-inhibitory and inhibitory concentration regimes based on bootstrap confidence intervals.\relax }{table.caption.223}{}}
\@writefile{toc}{\contentsline {section}{\numberline {4.9}SI figures}{156}{section.4.9}\protected@file@percent }
\@writefile{lof}{\contentsline {figure}{\numberline {4.1}{\ignorespaces Single-drug timecourse data for the six antibiotics used in this study. Panels~(a--f) show the single-drug trajectories across \num {12} concentrations for amoxicillin, chloramphenicol, colistin, penicillin, polymyxin~B, and tetracycline, respectively. For each concentration we aggregate \num {20} replicate curves, obtained from five independent combination experiments with four technical replicates each. Lines represent the concentration-wise median over replicates at each measurement cycle, and shaded bands indicate the central 50\tmspace  +\thinmuskip {.1667em}\% percentile interval (25th--75th percentiles). Time on the horizontal axis corresponds to the per-cycle mean acquisition time across wells to account for \SI {200}{\milli \second } per-well readout staggering.\relax }}{157}{figure.caption.224}\protected@file@percent }
\newlabel{fig:single-timecourses}{{\M@TitleReference {4.1}{Single-drug timecourse data for the six antibiotics used in this study. Panels~(a--f) show the single-drug trajectories across \num {12} concentrations for amoxicillin, chloramphenicol, colistin, penicillin, polymyxin~B, and tetracycline, respectively. For each concentration we aggregate \num {20} replicate curves, obtained from five independent combination experiments with four technical replicates each. Lines represent the concentration-wise median over replicates at each measurement cycle, and shaded bands indicate the central 50\tmspace  +\thinmuskip {.1667em}\% percentile interval (25th--75th percentiles). Time on the horizontal axis corresponds to the per-cycle mean acquisition time across wells to account for \SI {200}{\milli \second } per-well readout staggering.\relax }}{157}{Single-drug timecourse data for the six antibiotics used in this study. Panels~(a--f) show the single-drug trajectories across \num {12} concentrations for amoxicillin, chloramphenicol, colistin, penicillin, polymyxin~B, and tetracycline, respectively. For each concentration we aggregate \num {20} replicate curves, obtained from five independent combination experiments with four technical replicates each. Lines represent the concentration-wise median over replicates at each measurement cycle, and shaded bands indicate the central 50\,\% percentile interval (25th--75th percentiles). Time on the horizontal axis corresponds to the per-cycle mean acquisition time across wells to account for \SI {200}{\milli \second } per-well readout staggering.\relax }{figure.caption.224}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {4.2}{\ignorespaces Single-drug pharmacodynamic (PD) curves corresponding to the timecourse data in \autoref  {fig:single-timecourses}. Panels~(a--f) show the net rate of population change as a function of drug concentration for amoxicillin, chloramphenicol, colistin, penicillin, polymyxin~B, and tetracycline, respectively. Curves are fitted to the same replicate-aggregated datasets as in \autoref  {fig:single-timecourses}, and intervals indicate uncertainty in the fitted PD relationship.\relax }}{158}{figure.caption.225}\protected@file@percent }
\newlabel{fig:single-pdcurves}{{\M@TitleReference {4.2}{Single-drug pharmacodynamic (PD) curves corresponding to the timecourse data in \autoref  {fig:single-timecourses}. Panels~(a--f) show the net rate of population change as a function of drug concentration for amoxicillin, chloramphenicol, colistin, penicillin, polymyxin~B, and tetracycline, respectively. Curves are fitted to the same replicate-aggregated datasets as in \autoref  {fig:single-timecourses}, and intervals indicate uncertainty in the fitted PD relationship.\relax }}{158}{Single-drug pharmacodynamic (PD) curves corresponding to the timecourse data in \autoref {fig:single-timecourses}. Panels~(a--f) show the net rate of population change as a function of drug concentration for amoxicillin, chloramphenicol, colistin, penicillin, polymyxin~B, and tetracycline, respectively. Curves are fitted to the same replicate-aggregated datasets as in \autoref {fig:single-timecourses}, and intervals indicate uncertainty in the fitted PD relationship.\relax }{figure.caption.225}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {4.3}{\ignorespaces Distribution of the effective net growth rate $\mitpsi $ across all drug combinations measured in checkerboard assays. Each panel corresponds to one drug pair, and each cell represents a single concentration condition. Colors indicate the median estimate of $\mitpsi $ across bootstrap resamples. Symbols indicate whether $\mitpsi $ differs significantly from zero: stars denote significantly positive growth, diamonds significantly negative growth. These effective growth rates are inferred from time-resolved luminescence trajectories as described in the Methods..\relax }}{159}{figure.caption.226}\protected@file@percent }
\newlabel{fig:psi}{{\M@TitleReference {4.3}{Distribution of the effective net growth rate $\mitpsi $ across all drug combinations measured in checkerboard assays. Each panel corresponds to one drug pair, and each cell represents a single concentration condition. Colors indicate the median estimate of $\mitpsi $ across bootstrap resamples. Symbols indicate whether $\mitpsi $ differs significantly from zero: stars denote significantly positive growth, diamonds significantly negative growth. These effective growth rates are inferred from time-resolved luminescence trajectories as described in the Methods..\relax }}{159}{Distribution of the effective net growth rate $\psi $ across all drug combinations measured in checkerboard assays. Each panel corresponds to one drug pair, and each cell represents a single concentration condition. Colors indicate the median estimate of $\psi $ across bootstrap resamples. Symbols indicate whether $\psi $ differs significantly from zero: stars denote significantly positive growth, diamonds significantly negative growth. These effective growth rates are inferred from time-resolved luminescence trajectories as described in the Methods..\relax }{figure.caption.226}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {4.4}{\ignorespaces Bliss interaction classification based on bootstrap inference of treatment effects. For each concentration pair, treatment effects were resampled to obtain a distribution of the Bliss interaction index $\mitmu $. Cells are colored according to statistical significance: teal indicates synergistic interactions (95\% confidence interval entirely below zero), orange indicates antagonistic interactions (95\% confidence interval entirely above zero), and white indicates no significant deviation from additivity. All estimates are based on effective growth rates $\mitpsi $ inferred from checkerboard experiments..\relax }}{160}{figure.caption.227}\protected@file@percent }
\newlabel{fig:mu_interaction_heatmap}{{\M@TitleReference {4.4}{Bliss interaction classification based on bootstrap inference of treatment effects. For each concentration pair, treatment effects were resampled to obtain a distribution of the Bliss interaction index $\mitmu $. Cells are colored according to statistical significance: teal indicates synergistic interactions (95\% confidence interval entirely below zero), orange indicates antagonistic interactions (95\% confidence interval entirely above zero), and white indicates no significant deviation from additivity. All estimates are based on effective growth rates $\mitpsi $ inferred from checkerboard experiments..\relax }}{160}{Bliss interaction classification based on bootstrap inference of treatment effects. For each concentration pair, treatment effects were resampled to obtain a distribution of the Bliss interaction index $\mu $. Cells are colored according to statistical significance: teal indicates synergistic interactions (95\% confidence interval entirely below zero), orange indicates antagonistic interactions (95\% confidence interval entirely above zero), and white indicates no significant deviation from additivity. All estimates are based on effective growth rates $\psi $ inferred from checkerboard experiments..\relax }{figure.caption.227}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {4.5}{\ignorespaces Loewe interaction classification based on bootstrap inference of treatment effects. For each concentration pair, bootstrap samples were used to compute a distribution of the fractional inhibitory concentration index (FICI). Teal indicates significant synergy (95\% confidence interval entirely below 1), orange indicates significant antagonism (95\% confidence interval entirely above 1), and white indicates no significant deviation from Loewe additivity. All estimates are derived from effective growth rates $\mitpsi $ obtained from checkerboard assays..\relax }}{161}{figure.caption.228}\protected@file@percent }
\newlabel{fig:fici_interaction_heatmap}{{\M@TitleReference {4.5}{Loewe interaction classification based on bootstrap inference of treatment effects. For each concentration pair, bootstrap samples were used to compute a distribution of the fractional inhibitory concentration index (FICI). Teal indicates significant synergy (95\% confidence interval entirely below 1), orange indicates significant antagonism (95\% confidence interval entirely above 1), and white indicates no significant deviation from Loewe additivity. All estimates are derived from effective growth rates $\mitpsi $ obtained from checkerboard assays..\relax }}{161}{Loewe interaction classification based on bootstrap inference of treatment effects. For each concentration pair, bootstrap samples were used to compute a distribution of the fractional inhibitory concentration index (FICI). Teal indicates significant synergy (95\% confidence interval entirely below 1), orange indicates significant antagonism (95\% confidence interval entirely above 1), and white indicates no significant deviation from Loewe additivity. All estimates are derived from effective growth rates $\psi $ obtained from checkerboard assays..\relax }{figure.caption.228}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {4.6}{\ignorespaces  Comparison of Loewe and Bliss interaction scores in two growth regimes. (a) Inhibitory (super-MIC) concentrations. (b) Sub-inhibitory (sub-MIC) concentrations. Each point represents a drug combination with error bars indicating bootstrap confidence intervals. Colors encode agreement or disagreement between Loewe and Bliss classifications. \relax }}{162}{figure.caption.229}\protected@file@percent }
\newlabel{fig:si-loewe-vs-bliss-2d}{{\M@TitleReference {4.6}{ Comparison of Loewe and Bliss interaction scores in two growth regimes. (a) Inhibitory (super-MIC) concentrations. (b) Sub-inhibitory (sub-MIC) concentrations. Each point represents a drug combination with error bars indicating bootstrap confidence intervals. Colors encode agreement or disagreement between Loewe and Bliss classifications. \relax }}{162}{ Comparison of Loewe and Bliss interaction scores in two growth regimes. (a) Inhibitory (super-MIC) concentrations. (b) Sub-inhibitory (sub-MIC) concentrations. Each point represents a drug combination with error bars indicating bootstrap confidence intervals. Colors encode agreement or disagreement between Loewe and Bliss classifications. \relax }{figure.caption.229}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {4.7}{\ignorespaces Effective net growth rate surfaces $\mitpsi $ for all drug combinations. Each panel shows the median effective growth rate estimated from time-resolved luminescence trajectories across the concentration grid. Colors indicate the magnitude of $\mitpsi $, with negative values corresponding to net killing and positive values to net growth. All panels share a common color scale to allow direct comparison across drug pairs.\relax }}{163}{figure.caption.230}\protected@file@percent }
\newlabel{fig:surface_psi}{{\M@TitleReference {4.7}{Effective net growth rate surfaces $\mitpsi $ for all drug combinations. Each panel shows the median effective growth rate estimated from time-resolved luminescence trajectories across the concentration grid. Colors indicate the magnitude of $\mitpsi $, with negative values corresponding to net killing and positive values to net growth. All panels share a common color scale to allow direct comparison across drug pairs.\relax }}{163}{Effective net growth rate surfaces $\psi $ for all drug combinations. Each panel shows the median effective growth rate estimated from time-resolved luminescence trajectories across the concentration grid. Colors indicate the magnitude of $\psi $, with negative values corresponding to net killing and positive values to net growth. All panels share a common color scale to allow direct comparison across drug pairs.\relax }{figure.caption.230}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {4.8}{\ignorespaces  Polar pharmacodynamic curves for all drug combinations. For each drug pair, we show one-dimensional cuts through the \(\mitpsi \)-surface splines at \(\mitphi =45^\circ \) (equal mixing in units of \(\mathrm {zMIC}\)), plotting \(\mitpsi \) as a function of the combined dose \(z\). The blue dotted line marks \(z=1/\sqrt  {2}\), corresponding to both single-drug doses being at \(0.5\tmspace  +\thinmuskip {.1667em}\mathrm {zMIC}\), and the blue dashed line marks \(z=\sqrt  {2}\), corresponding to both being at \(1\tmspace  +\thinmuskip {.1667em}\mathrm {zMIC}\). Solid curves show the median surface-derived \(\mitpsi \), with corresponding Bliss- and Loewe-based predictions evaluated along the same trajectory. \relax }}{164}{figure.caption.231}\protected@file@percent }
\newlabel{fig:surface_pd}{{\M@TitleReference {4.8}{ Polar pharmacodynamic curves for all drug combinations. For each drug pair, we show one-dimensional cuts through the \(\mitpsi \)-surface splines at \(\mitphi =45^\circ \) (equal mixing in units of \(\mathrm {zMIC}\)), plotting \(\mitpsi \) as a function of the combined dose \(z\). The blue dotted line marks \(z=1/\sqrt  {2}\), corresponding to both single-drug doses being at \(0.5\tmspace  +\thinmuskip {.1667em}\mathrm {zMIC}\), and the blue dashed line marks \(z=\sqrt  {2}\), corresponding to both being at \(1\tmspace  +\thinmuskip {.1667em}\mathrm {zMIC}\). Solid curves show the median surface-derived \(\mitpsi \), with corresponding Bliss- and Loewe-based predictions evaluated along the same trajectory. \relax }}{164}{ Polar pharmacodynamic curves for all drug combinations. For each drug pair, we show one-dimensional cuts through the \(\psi \)-surface splines at \(\phi =45^\circ \) (equal mixing in units of \(\mathrm {zMIC}\)), plotting \(\psi \) as a function of the combined dose \(z\). The blue dotted line marks \(z=1/\sqrt {2}\), corresponding to both single-drug doses being at \(0.5\,\mathrm {zMIC}\), and the blue dashed line marks \(z=\sqrt {2}\), corresponding to both being at \(1\,\mathrm {zMIC}\). Solid curves show the median surface-derived \(\psi \), with corresponding Bliss- and Loewe-based predictions evaluated along the same trajectory. \relax }{figure.caption.231}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {4.9}{\ignorespaces Isoboles of constant effective growth rate $\mitpsi $ derived from the interpolated response surfaces. Each panel shows curves of equal $\mitpsi $ in concentration space, illustrating deviations from linear additivity. Bending toward the origin indicates synergistic interactions, whereas outward bending indicates antagonism.\relax }}{165}{figure.caption.232}\protected@file@percent }
\newlabel{fig:surface_isoboles}{{\M@TitleReference {4.9}{Isoboles of constant effective growth rate $\mitpsi $ derived from the interpolated response surfaces. Each panel shows curves of equal $\mitpsi $ in concentration space, illustrating deviations from linear additivity. Bending toward the origin indicates synergistic interactions, whereas outward bending indicates antagonism.\relax }}{165}{Isoboles of constant effective growth rate $\psi $ derived from the interpolated response surfaces. Each panel shows curves of equal $\psi $ in concentration space, illustrating deviations from linear additivity. Bending toward the origin indicates synergistic interactions, whereas outward bending indicates antagonism.\relax }{figure.caption.232}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {4.10}{\ignorespaces  Angular interaction profiles for all drug combinations. For each drug pair, we extract isoboles (paths of constant \(\mitpsi \)) from the consensus \(\mitpsi \)-surface and evaluate Bliss- and Loewe-based predictions for \(\mitpsi \) along these paths $(z, \mitphi )$, plotted as a function of the mixing angle \(\mitphi \). Each combination is shown for one sub-inhibitory isobole, the MIC isobole, and one inhibitory isobole. \relax }}{166}{figure.caption.233}\protected@file@percent }
\newlabel{fig:surface_angular_interaction}{{\M@TitleReference {4.10}{ Angular interaction profiles for all drug combinations. For each drug pair, we extract isoboles (paths of constant \(\mitpsi \)) from the consensus \(\mitpsi \)-surface and evaluate Bliss- and Loewe-based predictions for \(\mitpsi \) along these paths $(z, \mitphi )$, plotted as a function of the mixing angle \(\mitphi \). Each combination is shown for one sub-inhibitory isobole, the MIC isobole, and one inhibitory isobole. \relax }}{166}{ Angular interaction profiles for all drug combinations. For each drug pair, we extract isoboles (paths of constant \(\psi \)) from the consensus \(\psi \)-surface and evaluate Bliss- and Loewe-based predictions for \(\psi \) along these paths $(z, \phi )$, plotted as a function of the mixing angle \(\phi \). Each combination is shown for one sub-inhibitory isobole, the MIC isobole, and one inhibitory isobole. \relax }{figure.caption.233}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {4.11}{\ignorespaces Light noise distribution (shows the fraction of the original light intensity arriving in neighbouring wells; dependent on the distance to the source well; in well lengths $d_W$.\relax }}{167}{figure.caption.234}\protected@file@percent }
\newlabel{fig:light_distribution}{{\M@TitleReference {4.11}{Light noise distribution (shows the fraction of the original light intensity arriving in neighbouring wells; dependent on the distance to the source well; in well lengths $d_W$.\relax }}{167}{Light noise distribution (shows the fraction of the original light intensity arriving in neighbouring wells; dependent on the distance to the source well; in well lengths $d_W$.\relax }{figure.caption.234}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {4.12}{\ignorespaces Slope of the inoculum effect ($\mathrm {d}\mitpsi /\mathrm {d}I_0$) as a function of drug concentration. For each drug and concentration, slopes ($\mathrm {d}\mitpsi /\mathrm {d}I_0$) are obtained by regressing the observed net growth rates across inocula. Crosses denote concentrations with non-significant inoculum effects, whereas stars indicate statistically significant effects. \relax }}{168}{figure.caption.235}\protected@file@percent }
\newlabel{fig:inoculum}{{\M@TitleReference {4.12}{Slope of the inoculum effect ($\mathrm {d}\mitpsi /\mathrm {d}I_0$) as a function of drug concentration. For each drug and concentration, slopes ($\mathrm {d}\mitpsi /\mathrm {d}I_0$) are obtained by regressing the observed net growth rates across inocula. Crosses denote concentrations with non-significant inoculum effects, whereas stars indicate statistically significant effects. \relax }}{168}{Slope of the inoculum effect ($\mathrm {d}\psi /\mathrm {d}I_0$) as a function of drug concentration. For each drug and concentration, slopes ($\mathrm {d}\psi /\mathrm {d}I_0$) are obtained by regressing the observed net growth rates across inocula. Crosses denote concentrations with non-significant inoculum effects, whereas stars indicate statistically significant effects. \relax }{figure.caption.235}{}}
\abx@aux@refsection{9}{171}
\@writefile{lof}{\addvspace {10pt}}
\@writefile{lot}{\addvspace {10pt}}
\@writefile{toc}{\contentsline {chapter}{\chapternumberline {5}Concluding Remarks}{171}{chapter.5}\protected@file@percent }
\newlabel{refsection:9}{{\M@TitleReference {5}{Concluding Remarks}}{171}{Concluding Remarks}{chapter.5}{}}
\@writefile{toc}{\contentsline {section}{\numberline {5.1}Is combination therapy the best treatment strategy?}{171}{section.5.1}\protected@file@percent }
\abx@aux@cite{Gregory2018}
\abx@aux@segm{9}{0}{Gregory2018}
\abx@aux@cite{Kishony2003}
\abx@aux@segm{9}{0}{Kishony2003}
\@writefile{toc}{\contentsline {section}{\numberline {5.2}Can luminescence serve as a proxy for net growth?}{173}{section.5.2}\protected@file@percent }
\abx@aux@cite{Edgeworth2020}
\abx@aux@segm{9}{0}{Edgeworth2020}
\abx@aux@cite{Schwaber2011}
\abx@aux@segm{9}{0}{Schwaber2011}
\abx@aux@cite{Kyaw2006}
\abx@aux@segm{9}{0}{Kyaw2006}
\@writefile{toc}{\contentsline {section}{\numberline {5.3}Can interaction data from sub-MIC concentrations be extrapolated to the killing range?}{174}{section.5.3}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {5.4}General concluding note}{174}{section.5.4}\protected@file@percent }
\abx@aux@number{26}{Kirby1944}{2}{none/global//global/global}{1}
\abx@aux@number{27}{Naghavi2024}{2}{none/global//global/global}{2}
\abx@aux@number{28}{Bates1998}{2}{none/global//global/global}{3}
\abx@aux@number{29}{Regoes2004}{2}{none/global//global/global}{4}
\abx@aux@number{30}{Bell2014}{2}{none/global//global/global}{5}
\abx@aux@number{31}{Rahman2023}{2}{none/global//global/global}{6}
\abx@aux@number{32}{Leekha2011}{2}{none/global//global/global}{7}
\abx@aux@number{33}{Kable1980}{2}{none/global//global/global}{8}
\abx@aux@number{34}{Delp1980}{2}{none/global//global/global}{9}
\abx@aux@number{35}{Skylakakis1981}{2}{none/global//global/global}{10}
\abx@aux@number{36}{Bonhoeffer1997}{2}{none/global//global/global}{11}
\abx@aux@number{37}{Tepekule2017}{2}{none/global//global/global}{12}
\abx@aux@number{38}{Uecker2021}{2}{none/global//global/global}{13}
\abx@aux@number{39}{Jernberg2007}{2}{none/global//global/global}{14}
\abx@aux@number{40}{Tamma2012}{2}{none/global//global/global}{15}
\abx@aux@number{41}{Goldberg2012}{2}{none/global//global/global}{16}
\abx@aux@number{42}{siedentop_metaanalysis_2024}{2}{none/global//global/global}{17}
\abx@aux@number{43}{Angst2021}{2}{none/global//global/global}{18}
\abx@aux@number{44}{Loewe1926}{2}{none/global//global/global}{19}
\abx@aux@number{45}{Bliss1939}{2}{none/global//global/global}{20}
\abx@aux@number{46}{Yeh2006}{2}{none/global//global/global}{21}
\abx@aux@number{47}{Chevereau2015a}{2}{none/global//global/global}{22}
\abx@aux@number{48}{Kavcic2020}{2}{none/global//global/global}{23}
\abx@aux@number{69}{Kable1980}{3}{none/global//global/global}{1}
\abx@aux@number{70}{Delp1980}{3}{none/global//global/global}{2}
\abx@aux@number{71}{Skylakakis1981}{3}{none/global//global/global}{3}
\abx@aux@number{72}{Goldberg2012}{3}{none/global//global/global}{4}
\abx@aux@number{73}{siedentop_metaanalysis_2024}{3}{none/global//global/global}{5}
\abx@aux@number{74}{VanDuijn2018}{3}{none/global//global/global}{6}
\abx@aux@number{75}{Uecker2021}{3}{none/global//global/global}{7}
\abx@aux@number{76}{Bonhoeffer1997}{3}{none/global//global/global}{8}
\abx@aux@number{77}{Tepekule2017}{3}{none/global//global/global}{9}
\abx@aux@number{78}{Angst2021}{3}{none/global//global/global}{10}
\abx@aux@number{79}{Huisman2022}{3}{none/global//global/global}{11}
\abx@aux@number{80}{Sutter2016}{3}{none/global//global/global}{12}
\abx@aux@number{81}{eucast_disk2024}{3}{none/global//global/global}{13}
\abx@aux@number{82}{BAG2015}{3}{none/global//global/global}{14}
\abx@aux@number{83}{Headd2018}{3}{none/global//global/global}{15}
\abx@aux@number{84}{Feher2012}{3}{none/global//global/global}{16}
\abx@aux@number{105}{Sutter2016}{4}{none/global//global/global}{1}
\abx@aux@number{106}{Huisman2022}{4}{none/global//global/global}{2}
\abx@aux@number{107}{Feher2012}{4}{none/global//global/global}{3}
\abx@aux@number{108}{Carattoli2005}{4}{none/global//global/global}{4}
\abx@aux@number{109}{Huisman2022Conjugation}{4}{none/global//global/global}{5}
\abx@aux@number{110}{Virtanen2020}{4}{none/global//global/global}{6}
\abx@aux@number{111}{seabold2010statsmodels}{4}{none/global//global/global}{7}
\abx@aux@number{112}{Cates1951}{4}{none/global//global/global}{8}
\abx@aux@number{113}{Jawetz1957}{4}{none/global//global/global}{9}
\abx@aux@number{114}{Ocampo2014}{4}{none/global//global/global}{10}
\abx@aux@number{115}{Angermayr2022}{4}{none/global//global/global}{11}
\abx@aux@number{175}{Regoes2004}{5}{none/global//global/global}{1}
\abx@aux@number{176}{Foerster2016}{5}{none/global//global/global}{2}
\abx@aux@number{177}{Vellend1977}{5}{none/global//global/global}{3}
\abx@aux@number{178}{Jacobs1993}{5}{none/global//global/global}{4}
\abx@aux@number{179}{Loeliger2003}{5}{none/global//global/global}{5}
\abx@aux@number{180}{Engebrecht1985}{5}{none/global//global/global}{6}
\abx@aux@number{181}{Meighen1991}{5}{none/global//global/global}{7}
\abx@aux@number{182}{Kishony2003}{5}{none/global//global/global}{8}
\abx@aux@number{183}{Yeh2006}{5}{none/global//global/global}{9}
\abx@aux@number{184}{Chait2007}{5}{none/global//global/global}{10}
\abx@aux@number{185}{Larsson2014}{5}{none/global//global/global}{11}
\abx@aux@number{186}{Kavcic2020}{5}{none/global//global/global}{12}
\abx@aux@number{187}{Angermayr2022}{5}{none/global//global/global}{13}
\abx@aux@number{188}{Salisbury1999}{5}{none/global//global/global}{14}
\abx@aux@number{189}{Beard2002}{5}{none/global//global/global}{15}
\abx@aux@number{190}{Alloush2003}{5}{none/global//global/global}{16}
\abx@aux@number{191}{Wang2010}{5}{none/global//global/global}{17}
\abx@aux@number{192}{Eagle1949}{5}{none/global//global/global}{18}
\abx@aux@number{193}{Besnard2002}{5}{none/global//global/global}{19}
\abx@aux@number{194}{Oliver2005}{5}{none/global//global/global}{20}
\abx@aux@number{195}{Li2014}{5}{none/global//global/global}{21}
\abx@aux@number{196}{Pearson1980}{5}{none/global//global/global}{22}
\abx@aux@number{197}{Eng1991}{5}{none/global//global/global}{23}
\abx@aux@number{198}{Coates2018}{5}{none/global//global/global}{24}
\abx@aux@number{199}{Marques2005}{5}{none/global//global/global}{25}
\abx@aux@number{200}{Levine1998}{5}{none/global//global/global}{26}
\abx@aux@number{201}{Wu2024}{5}{none/global//global/global}{27}
\abx@aux@number{202}{Fanous2025}{5}{none/global//global/global}{28}
\abx@aux@number{203}{Gleckman1981}{5}{none/global//global/global}{29}
\abx@aux@number{204}{Deslouches2005}{5}{none/global//global/global}{30}
\abx@aux@number{205}{Baquero1986}{5}{none/global//global/global}{31}
\abx@aux@number{206}{Deguchi2011}{5}{none/global//global/global}{32}
\abx@aux@number{207}{Cayron2023}{5}{none/global//global/global}{33}
\abx@aux@number{208}{Datsenko2000}{5}{none/global//global/global}{34}
\abx@aux@number{209}{Hughes2015}{5}{none/global//global/global}{35}
\abx@aux@number{210}{Bjarnason2003}{5}{none/global//global/global}{36}
\abx@aux@number{211}{EUCAST2025}{5}{none/global//global/global}{37}
\abx@aux@number{212}{Jett1997}{5}{none/global//global/global}{38}
\abx@aux@number{219}{Coates2018}{6}{none/global//global/global}{1}
\abx@aux@number{220}{Novozhilov2006}{6}{none/global//global/global}{2}
\abx@aux@number{221}{Kendall1948}{6}{none/global//global/global}{3}
\abx@aux@number{222}{Feller1939}{6}{none/global//global/global}{4}
\abx@aux@number{223}{soft_code}{6}{none/global//global/global}{5}
\abx@aux@number{269}{Naghavi2024}{7}{none/global//global/global}{1}
\abx@aux@number{270}{Witzany2020}{7}{none/global//global/global}{2}
\abx@aux@number{271}{Gulick1997}{7}{none/global//global/global}{3}
\abx@aux@number{272}{Goldberg2012}{7}{none/global//global/global}{4}
\abx@aux@number{273}{Bonhoeffer1997}{7}{none/global//global/global}{5}
\abx@aux@number{274}{Tepekule2017}{7}{none/global//global/global}{6}
\abx@aux@number{275}{Uecker2021}{7}{none/global//global/global}{7}
\abx@aux@number{276}{Angst2021}{7}{none/global//global/global}{8}
\abx@aux@number{277}{Muetter2024}{7}{none/global//global/global}{9}
\abx@aux@number{278}{Siedentop2024}{7}{none/global//global/global}{10}
\abx@aux@number{279}{Foucquier2015}{7}{none/global//global/global}{11}
\abx@aux@number{280}{Duarte2022}{7}{none/global//global/global}{12}
\abx@aux@number{281}{Bliss1939}{7}{none/global//global/global}{13}
\abx@aux@number{282}{Loewe1926}{7}{none/global//global/global}{14}
\abx@aux@number{283}{Baeder2016}{7}{none/global//global/global}{15}
\abx@aux@number{284}{Frei1913}{7}{none/global//global/global}{16}
\abx@aux@number{285}{Regoes2004}{7}{none/global//global/global}{17}
\abx@aux@number{286}{Yeh2006}{7}{none/global//global/global}{18}
\abx@aux@number{287}{OShaughnessy2006}{7}{none/global//global/global}{19}
\abx@aux@number{288}{Chevereau2015}{7}{none/global//global/global}{20}
\abx@aux@number{289}{Russ2018}{7}{none/global//global/global}{21}
\abx@aux@number{290}{Katzir2019}{7}{none/global//global/global}{22}
\abx@aux@number{291}{Kavcic2020}{7}{none/global//global/global}{23}
\abx@aux@number{292}{Rezzoagli2020}{7}{none/global//global/global}{24}
\abx@aux@number{293}{Sanchez-Hevia2025}{7}{none/global//global/global}{25}
\abx@aux@number{294}{huntelman2023}{7}{none/global//global/global}{26}
\abx@aux@number{295}{Yang2017}{7}{none/global//global/global}{27}
\abx@aux@number{296}{Ruden2019}{7}{none/global//global/global}{28}
\abx@aux@number{297}{Liu2022}{7}{none/global//global/global}{29}
\abx@aux@number{298}{Ocampo2014}{7}{none/global//global/global}{30}
\abx@aux@number{299}{Rao2017}{7}{none/global//global/global}{31}
\abx@aux@number{300}{Yu2016}{7}{none/global//global/global}{32}
\abx@aux@number{301}{Caballero2018}{7}{none/global//global/global}{33}
\abx@aux@number{302}{Chen2020}{7}{none/global//global/global}{34}
\abx@aux@number{303}{Bognar2024}{7}{none/global//global/global}{35}
\abx@aux@number{304}{Yu2018}{7}{none/global//global/global}{36}
\abx@aux@number{305}{Chou1984}{7}{none/global//global/global}{37}
\abx@aux@number{306}{Meletiadis2007}{7}{none/global//global/global}{38}
\abx@aux@number{307}{Kavcic2021}{7}{none/global//global/global}{39}
\abx@aux@number{310}{Bliss1939}{8}{none/global//global/global}{1}
\abx@aux@number{311}{Pedregosa2011}{8}{none/global//global/global}{2}
\abx@aux@number{316}{Kishony2003}{9}{none/global//global/global}{1}
\abx@aux@number{317}{Edgeworth2020}{9}{none/global//global/global}{2}
\abx@aux@number{318}{Schwaber2011}{9}{none/global//global/global}{3}
\abx@aux@number{319}{Kyaw2006}{9}{none/global//global/global}{4}
\abx@aux@refcontextdefaultsdone
\abx@aux@defaultrefcontext{2}{Kirby1944}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Naghavi2024}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Bates1998}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Regoes2004}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Bell2014}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Rahman2023}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Leekha2011}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Kable1980}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Delp1980}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Skylakakis1981}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Bonhoeffer1997}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Tepekule2017}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Uecker2021}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Jernberg2007}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Tamma2012}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Goldberg2012}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{siedentop_metaanalysis_2024}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Angst2021}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Loewe1926}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Bliss1939}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Yeh2006}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Chevereau2015a}{none/global//global/global}
\abx@aux@defaultrefcontext{2}{Kavcic2020}{none/global//global/global}
\abx@aux@defaultrefcontext{3}{Kable1980}{none/global//global/global}
\abx@aux@defaultrefcontext{3}{Delp1980}{none/global//global/global}
\abx@aux@defaultrefcontext{3}{Skylakakis1981}{none/global//global/global}
\abx@aux@defaultrefcontext{3}{Goldberg2012}{none/global//global/global}
\abx@aux@defaultrefcontext{3}{siedentop_metaanalysis_2024}{none/global//global/global}
\abx@aux@defaultrefcontext{3}{VanDuijn2018}{none/global//global/global}
\abx@aux@defaultrefcontext{3}{Uecker2021}{none/global//global/global}
\abx@aux@defaultrefcontext{3}{Bonhoeffer1997}{none/global//global/global}
\abx@aux@defaultrefcontext{3}{Tepekule2017}{none/global//global/global}
\abx@aux@defaultrefcontext{3}{Angst2021}{none/global//global/global}
\abx@aux@defaultrefcontext{3}{Huisman2022}{none/global//global/global}
\abx@aux@defaultrefcontext{3}{Sutter2016}{none/global//global/global}
\abx@aux@defaultrefcontext{3}{eucast_disk2024}{none/global//global/global}
\abx@aux@defaultrefcontext{3}{BAG2015}{none/global//global/global}
\abx@aux@defaultrefcontext{3}{Headd2018}{none/global//global/global}
\abx@aux@defaultrefcontext{3}{Feher2012}{none/global//global/global}
\abx@aux@defaultrefcontext{4}{Sutter2016}{none/global//global/global}
\abx@aux@defaultrefcontext{4}{Huisman2022}{none/global//global/global}
\abx@aux@defaultrefcontext{4}{Feher2012}{none/global//global/global}
\abx@aux@defaultrefcontext{4}{Carattoli2005}{none/global//global/global}
\abx@aux@defaultrefcontext{4}{Huisman2022Conjugation}{none/global//global/global}
\abx@aux@defaultrefcontext{4}{Virtanen2020}{none/global//global/global}
\abx@aux@defaultrefcontext{4}{seabold2010statsmodels}{none/global//global/global}
\abx@aux@defaultrefcontext{4}{Cates1951}{none/global//global/global}
\abx@aux@defaultrefcontext{4}{Jawetz1957}{none/global//global/global}
\abx@aux@defaultrefcontext{4}{Ocampo2014}{none/global//global/global}
\abx@aux@defaultrefcontext{4}{Angermayr2022}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Regoes2004}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Foerster2016}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Vellend1977}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Jacobs1993}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Loeliger2003}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Engebrecht1985}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Meighen1991}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Kishony2003}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Yeh2006}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Chait2007}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Larsson2014}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Kavcic2020}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Angermayr2022}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Salisbury1999}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Beard2002}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Alloush2003}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Wang2010}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Eagle1949}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Besnard2002}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Oliver2005}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Li2014}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Pearson1980}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Eng1991}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Coates2018}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Marques2005}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Levine1998}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Wu2024}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Fanous2025}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Gleckman1981}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Deslouches2005}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Baquero1986}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Deguchi2011}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Cayron2023}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Datsenko2000}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Hughes2015}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Bjarnason2003}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{EUCAST2025}{none/global//global/global}
\abx@aux@defaultrefcontext{5}{Jett1997}{none/global//global/global}
\abx@aux@defaultrefcontext{6}{Coates2018}{none/global//global/global}
\abx@aux@defaultrefcontext{6}{Novozhilov2006}{none/global//global/global}
\abx@aux@defaultrefcontext{6}{Kendall1948}{none/global//global/global}
\abx@aux@defaultrefcontext{6}{Feller1939}{none/global//global/global}
\abx@aux@defaultrefcontext{6}{soft_code}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Naghavi2024}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Witzany2020}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Gulick1997}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Goldberg2012}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Bonhoeffer1997}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Tepekule2017}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Uecker2021}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Angst2021}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Muetter2024}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Siedentop2024}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Foucquier2015}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Duarte2022}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Bliss1939}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Loewe1926}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Baeder2016}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Frei1913}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Regoes2004}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Yeh2006}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{OShaughnessy2006}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Chevereau2015}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Russ2018}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Katzir2019}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Kavcic2020}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Rezzoagli2020}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Sanchez-Hevia2025}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{huntelman2023}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Yang2017}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Ruden2019}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Liu2022}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Ocampo2014}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Rao2017}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Yu2016}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Caballero2018}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Chen2020}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Bognar2024}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Yu2018}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Chou1984}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Meletiadis2007}{none/global//global/global}
\abx@aux@defaultrefcontext{7}{Kavcic2021}{none/global//global/global}
\abx@aux@defaultrefcontext{8}{Bliss1939}{none/global//global/global}
\abx@aux@defaultrefcontext{8}{Pedregosa2011}{none/global//global/global}
\abx@aux@defaultrefcontext{9}{Kishony2003}{none/global//global/global}
\abx@aux@defaultrefcontext{9}{Edgeworth2020}{none/global//global/global}
\abx@aux@defaultrefcontext{9}{Schwaber2011}{none/global//global/global}
\abx@aux@defaultrefcontext{9}{Kyaw2006}{none/global//global/global}
\memsetcounter{lastsheet}{186}
\memsetcounter{lastpage}{176}
